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Abstract 
The implications of DNA hypomethylation and hypermethylation in the etiology of  
tumorigenesis have become quite clear. Since epigenetic modifications are reversible, 
methylation studies are extremely promising to better characterize colorectal cancer 
(CRC) and to identify new tools for diagnosis and prognosis.  In the frame of a wider 
study ongoing aimed at searching for possible  correlations among genetic, epigenetic 
and environmental factors in colorectal cancer, this thesis  took into account a cohort of 
CRC subjects  until now recruited, focusing on the following items: 1) the validation of  
the MS-HRM protocol, used for the methylation analysis, by comparing it with a widely 
employed technique (Pyrosequencing); 2) the evaluation of the influence of an 
immunomagnetic method with microbeads coated with the antibody CD326+, specific 
for epithelial cells, to clarify if cancer epithelial cells from the surgically resected CRC 
tissue could give more accurate results in DNA  methylation  levels detection with 
respect to the whole CRC tissue; 3) the detection of methylation levels (performed by 
MS-HRM) in promoters of of APC, CDKN2A, hMLH1, MGMT and RASSF1A genes in 
CRC and healthy adjacent tissue specimens; 4) the analysis of the correlation among the 
methylation status of the chosen genes and the clinical-pathological features of the 
patients; 5) the analysis of the correlation among MTHFR C677T, DNMT3B C-149T  
polymorphisms and the methylation levels of APC, CDKN2A, hMLH1 and MGMT gene 
promoters. Results obtained by using MS-HRM and Pyrosequencing have shown to be 
quantitatively comparable. No statistically significant difference between the epithelial 
cells CD326+ fraction and the whole tissue about the promoter methylation of APC, 
CDKN2A, MGMT and hMLH1 genes was observed, although some patients showed 
individually a statistically significant difference between the two experimental 
 II 
 
conditions regarding the degree of methylation of these genes. It was also seen, for all 
of the studied genes, a higher methylation level in CRC tissue respect to the healthy 
adjacent tissue. No statistically significant association between stage (TNM), gender, 
sex, tumor size, and location with regard to the methylation profile of each of the 
analyzed genes was found in the examined cohort. However, it was found an interesting 
positive association between age and both hMLH1 (P value= 0.007) and MGMT (P 
value= 0.03).  Finally significant interactions between MTHFR 677C>T, DNMT3B -
149C>T polymorphisms and gene promoter methylation were observed. 
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Introduction 
1. Colorectal cancer   
The digestive surface of the human large intestine is characterized by a monolayer of 
specialized epithelial cells that forms crypts. The first recognizable manifestation of 
epithelial alteration during colorectal tumor development are the Aberrant Crypt Foci 
(ACF), small hyper- or dysplastic lesions. Larger ACF with altered morphology, 
dysplastic histology and associated gene mutations are high-risk candidates for 
adenoma and CRC formation. According to the their architecture, adenomas may be 
divided in tubular, when coarsely lobulated and pedunculated, or villous, when sessile, 
covering a broad area directly onto the muscularis mucosae (the muscle layer 
underlying the epithelial lining) and submucosa (the underlying stromal layer). Villous 
adenomas are thought to have higher risk of malignant progression. The carcinoma in 
situ are advanced high dysplastic lesions still confined within the epithelial layer. 
Finally, malignant adeno-carcinomas are characterized by the ability to invade the 
surrounding tissues through the muscularis mucosae and into the stromal compartment, 
and migrate to distal organs where they can form metastasis. The TNM Classification of 
Malignant Tumours (TNM) is a cancer staging system that describes the extent of 
cancer in a patient’s body: 
· T describes the size of the tumor and whether it has invaded nearby tissue, 
· N describes regional lymph nodes that are involved, 
· M describes distant metastasis (spread of cancer from one body part to 
another). 
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Particularly T represents the size or direct extent of the primary tumor (Tx: tumor 
cannot be evaluated, Tis: carcinoma in situ, T0: no signs of tumor and T1, T2, T3, T4: 
size and/or extension of the primary tumor); N represents the degree of spread to 
regional lymph nodes (Nx: lymph nodes cannot be evaluated, N0: tumor cells absent 
from regional lymph nodes, N1: regional lymph node metastasis present, N2: tumor 
spread to an extent between N1 and N3, N3: tumor spread to more distant or numerous 
regional lymph nodes; M represents the presence of metastasis (Mx: distant metastasis 
cannot be evaluated, M0: no distant metastasis, M1: metastasis to distant organs 
(beyond regional lymph nodes).  
The Stage grouping is as follow: 
Stage 0: Tis N0 M0 
Stage I: T1 N0 M0; T2 N0 M0: Cancer has begun to spread, but is still in the inner lining. 
Stage II: T3 N0 M0; T4 N0 M0: Cancer has spread to other organs near the colon or rectum. It 
has not reached lymph nodes. 
Stage III: any T, N1-2, M0: Cancer has spread to lymph nodes, but has not been carried to 
distant parts of the body. 
Stage IV: any T, any N, M1: Cancer has been carried through the lymph system to distant parts 
of the body. This is known as metastasis. The most likely organs to experience metastasis from 
colorectal cancer are the lungs and liver. 
 
1.1 Epidemiology 
CRC is the third most common cancer in men (663 000 cases, 10.0% of the total) and 
the second in women (571 000 cases, 9.4% of the total) worldwide (data observed in 
2008). Almost 60% of the cases occur in developed regions. The highest percentage is 
observed in Australia/New Zealand and Western Europe, the lowest in Africa (except 
Southern Africa) and South-Central Asia. Colorectal cancer is the fourth most common 
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cause of death from cancer (608 000 deaths worldwide, the 8% of all cancer deaths). 
Mortality rates are also lower in women than in men, except in the Caribbean. There is 
less variability in mortality rates worldwide (6-fold in men, 5-fold in women), with the 
highest mortality rates in both sexes estimated in Central and Eastern Europe and the 
lowest in Middle Africa (Figure 1). Table 1 shows the incidence, mortality and 
prevalence in the world for the year 2008 (Cancer Mondial, Globocan 2008). 
 
 
Figure 1: Estimated age-standardised rates (World) per 100,000 
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Table 1: Colorectal Cancer Incidence, Mortality and Prevalence Worldwide in 2008. 
 
Estimated numbers  Men Women Both sexes 
Cases Deaths 5-year 
prev. 
Cases Deaths 5-year 
prev. 
Cases Deaths 5-year 
prev. 
 World 663 320 1765 571 288 1495 1234 608 3260 
 More developed 
regions 
389 165 1141 338 154 968 727 319 2109 
 Less developed regions 274 154 624 232 134 526 506 288 1150 
 WHO Africa region  14 11 30 12 9 24 26 20 54 
 WHO Americas region  122 46 360 118 49 342 240 95 702 
 WHO East 
Mediterranean region 
13 9 29 10 7 23 23 16 52 
 WHO Europe region  238 115 645 212 107 564 450 222 1209 
 WHO South-East Asia 
region 
50 34 92 47 32 89 97 66 181 
 WHO Western Pacific 
region 
224 101 607 170 81 450 394 182 1057 
 IARC membership 
 (22 countries) 
372 154 1082 319 143 909 691 297 1991 
 United States of 
America 
79 24 245 74 26 227 153 50 472 
 China 125 61 289 95 48 219 220 109 508 
 India 20 14 27 16 11 21 36 25 48 
 European Union  182 80 507 151 68 417 333 148 924 
 
 
1.2 Genetics of colorectal cancer 
Most cases of colorectal cancer are sporadic. Risk factors include increasing age, male 
sex, previous colonic polyps or previous colorectal cancer, and environmental factors 
(red meat, high-fat diet, inadequate intake of fiber, obesity, sedentary lifestyle, diabetes 
mellitus, smoking, and high consumption of alcohol). Inflammatory bowel disease 
(ulcerative colitis and Chron’s disease) are two-thirds of the incidence, and the risk 
increases with duration of illness, severity and extent of inflammation.  
A number of familial syndromes are associated with a high risk of colorectal 
adenocarcinoma. FAP (Familial Adenomatous Polyposis) is an autosomal dominant 
condition due to different types of mutations in APC gene (Adenomatous polyposis 
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coli), which encodes a tumor suppressor that is part of the WNT signaling pathway (see 
below); its incidence varies from 1 in 7000 to 1 in 22000 births. The syndrome is more 
common in Western countries and it is characterized by more than 100 adenomatous 
polyps in the colon and rectum, developing after 10 years age. In addition to colonic 
polyps the syndrome can give rise to extraintestinal manifestations such as osteomas, 
epidermoid cysts, supernumerary teeth, thyroid tumors and brain tumors. By age 10 
years, 15% of FAP gene carriers manifest adenomas; by age 20 years, the probability 
rises to 75% and by 45 years the risk becomes 90% (www.cancer.gov). The average age 
of CRC diagnosis if untreated is 39 years; 7% develop CRC by age 21 and 95% by age 
50 (Jasperson et al., 2010). The clinical features of FAP appear to be generally 
associated with the location of the mutation in the APC gene and the type of mutation; 
for example a dense carpeting of colonic polyps is seen in patients with mutations 
between codons 169 and 1393. Figure 2 shows mutations in different regions of APC 
gene that correspond to variation in severity of symptoms. 
 
Figure 2: Mutations in APC gene cause FAP, but mutations in different regions of the gene will have a 
varying effect on the nature and severity of symptoms. 
 
The detection of APC mutation is approximately 80% using sequencing alone, such as 
the protein truncation assay (PTT). Studies reported whole exon deletion in 12% of 
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patients negative to APC sequencing test. Individuals at risk of FAP begin surveillance 
in the early teenage years (10-15 years). Colon surveillance should not be stopped in 
carriers of APC mutations because polyps sometime do not manifest until the fourth and 
fifth decades of life. Colectomy could be important when, in a FAP patient, numerous 
polyps have developed (>20) and when adenomas >1 cm are found or when advanced 
histology appears. Cyclooxigenase II inhibitors such as celecoxib and rofecoxib have 
been associated with a decrease in polyp size and number in FAP patients. Attenuated 
FAP is characterized by fewer adenomatous polyps (30, range 0-100) at colon and 
rectum than in classic FAP and is associated with particular subsets of APC mutations, 
including missense changes. Approximately 7% to 17% of patients with a FAP 
phenotype and without a detectable APC germline mutation carry the mutations in MYH 
gene. 
MYH associated polyposis (MAP) occurs in about 1/18000 CRC patients. MAP is 
caused by biallelic mutations in MYH, a gene involved in the base excision repair 
pathway to defend DNA against oxidative damage. This gene product prevents G:C to 
T:A transversions, caused by oxidative stress. The colonic phenotype of MAP mimics 
attenuated FAP, including propensity for proximal colonic neoplasms. There is also an 
association between hyperplastic or sessile serrated polyps (Jasperson et al., 2010).  
Individuals with Lynch syndrome (hereditary non-polyposis colorectal cancer/HNPCC) 
are predisposed to various types of cancers and are the 2-4% of all CRCs; in particular 
this syndrome occurs in about 1/300 people with colorectal cancer. Endometrial cancer 
is the most common extracolonic malignancy associated with Lynch syndrome; also 
other cancers such as gastric, ovarian, biliary, urinary tract, small bowel, brain are 
associated with HNPCC. It is an autosomal dominant condition caused by mutations in 
one of several DNA mismatch repair (MMR) genes. The mean age of CRC diagnosis in 
 7 
 
HNPCC syndrome mutation carriers is 44 years, compared with 64 years in sporadic 
cancer. Lifetime CRC risk is estimated to be 50-80%. Colon cancers arise in Lynch 
syndrome at a younger age of onset and a more proximal location compared to sporadic 
neoplasms; these types of tumor are poorly differentiated, mucinous. They are also 
characterized by a high level of microsatellite instability (MSI-H), a feature of cancers 
with mutations in MMR, necessary for maintaining genomic fidelity by correcting 
single base mismatches and insertion-deletion loops that form during DNA replication. 
Mutations in hMLH1 and hMLH2 account for the up to 90%. Mutations in hMSH6 
account for approximately 10% and mutations in hPMS2 are detected in rare occasions. 
The research criteria for defining Lynch syndrome families were established by the 
international collaborative group (ICG) meeting in Amsterdam in 1990 and are known 
as the Amsterdam criteria.  
Amsterdam criteria: 
1) One member diagnosed with colorectal cancer before age 50 years. 
2) Two affected generations 
3) Three affected relatives, one of them a first degree relative of the other two 
4) FAP should be excluded 
5) Tumor should be verified by pathological examination 
To increase sensitivity, the Amsterdam criteria were revised to obtain Amsterdam 
criteria II: 
1) There should be at least three relatives with a Lynch syndrome associated 
cancer (colorectal cancer or cancer of the endometrium, small bowel, ureter, 
or renal pelvis). 
2) One should be a first-degree relative of the other two 
3) At least two successive generations should be affected  
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4) At least one should be diagnosed before age 50 years 
5) Familial adenomatous polyposis should be excluded in the colorectal cancer 
cases 
6) Tumor should be verified by pathological examination. 
Another set of clinical criteria (Bethesda Guidelines) can be used to identify families 
with germline MMR mutations:  
1) Colorectal cancer diagnosed in an individual younger than 50 years. 
2) Presence of synchronous, metachronous colorectal, or other Lynch 
syndrome-associated tumor (i.e endometrial, stomach, etc) in an individual 
regardless of age. 
3) Colorectal cancer with MSI-high pathologic associated features diagnosed in 
an individual younger than 60 years 
4) Colorectal cancer or Lynch syndrome associated tumor diagnosed in at least 
one first-degree relative younger than 50 years. 
5) Colorectal cancer or Lynch syndrome-associated tumor diagnosed at any in 
two first degree, second-degree relatives.  
Genetic tests typically start with analysis of hMLH1 and hMLH2 by sequencing. 
Another approach for identifying Lynch syndrome, is to perform tumor testing when 
any of the Bethesda guidelines are identified. Approximately 90% Lynch syndrome 
associated CRC will have MSI-H, making this analysis very sensitive; sporadic MSI-H 
CRCs could be the result of somatic hypermethylation of the hMLH1 promoter region. 
Tumor testing with IHC utilizes four antibodies specific for hMLH1, hMSH2, hMSH6, 
hPMS2 proteins to evaluate tumor for MMR deficiency. Surveillance decrease both 
incidence and related deaths. Colonoscopies at 3-years intervals have been shown to 
decrease the risk of CRC by 50% and prevent CRC deaths. The reduction in CRC risk 
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and death is expected to be even greater when screening intervals are reduced to every 
1-2 years. Screening colonoscopy in affected individuals should be initiated by 20-25 
years of age and repeated every 1-2 years. Subtotal colectomy with ileorectal 
anastomosis is advised with the appearance of colon cancer. Population-based studies 
have led to estimates that 0.8%-2.3% of all CRC cases meet the Amsterdam criteria I 
and II for Lynch syndrome. A subset of these (40-70%) do not have MMR deficiency 
and have been termed familial colorectal cancer type X (that have lower CRC risk than 
HNPCC and do not exhibit MSI). Familial CRC arises from a number of different, 
lower-penetrance susceptibility genes than those associated with the well-defined, but 
rare inherited syndromes. No specific genetic markers are available for common 
familial CRC, then screening and surveillance are based on family history. Patients with 
a single first-degree relative older than age 60 years with colon cancer should receive 
average-risk colon cancer screening, but starting at age of 40 year; patients who have 
one relative with CRC before 60 years or two first degree relatives with CRC should be 
screened every 5 years by colonoscopy, starting at age 40 years, or at age 10 years 
younger than the earliest case in the family; patients with only second or third degree 
relatives with CRC should receive average-risk screening. The recommendations for 
screening average risk persons include these options: fecal occult blood screening each 
year, followed by colonoscopy; double contrast barium enema every 5-10 years; 
colonoscopy every 10 years. 
Rare Colon Cancer Syndromes: Peutz-Jeghers syndrome (PJS) is an early-onset 
autosomal dominant disorder characterized by small bowel and histologically 
distinctive hamartomatous polyps. Individuals with PJS have an estimated 81-93% 
lifetime risk of cancer. Germline mutations in the STK11 gene at chromosome 19p13.3 
(tumor suppressor gene) have been identified in approximately half of PJS families; a 
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study reported that 85% of individuals with PJS developed cancer by age 70. Juvenile 
polyposis syndrome (JPS) is a genetically heterogeneous, rare, childhood-onset, 
autosomal dominant disease due to germline mutations in the MADH4 gene 
(SMAD4/DPC4) in approximately 15-20% of cases and to mutations in BMPR1A gene 
in approximately 25-40% of cases. HPP is a rare condition characterized by multiple 
and/or large hyperplastic polyps of the colon. The World Health Organitation’s criteria 
for HPP include 30 cumulative hyperplastic polyps of any size distributed throughout 
the colon; >5 hyperplastic polyps proximal to the sigmoid colon with at least two >10 
mm in diameter; or at least 1 hyperplastic colonic polyp in an individual with a first-
degree relative with HPP. These conditions increase risk of CRC, which occurs on 
average in the 50s or 60s. The inheritance of HPP is weak, although both recessive and 
dominant transmission patterns have been proposed. Curiously, individuals with 
biallelic MUTYH mutations have been shown, on occasion, to meet criteria for HPP 
(Cunningham et al., 2010; Jasperson et al., 2010; www.cancer.gov). 
 
1.3 Cytogenetics of colorectal cancer  
For colorectal cancers, the acquisition of genomic instability is considered a key 
hallmark. Three major molecular subtypes can be recognized: MIN (or MSI, for 
“microsatellite instability”), CIN (for “chromosomal instability”) and CIMP (for “CpG 
islandmethylator phenotype”). MIN-CRC accounts for approximately 15%–20% of 
sporadic colorectal cancers. The characteristics of the three pathways (MIN, CIN, and 
CIMP) are not completely defined and thus they are not mutually exclusive; it is 
believed that a tumor can occasionally show features of multiple pathways, although the 
extent and nature of this overlap remains to be determined. CIN is the most common 
type of genomic instability observed in colon cancer and occurs in 80%–85% of 
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colorectal tumors. It occurs mainly in non-MIN cancers (or MSS for “microsatellite 
stable”) which are proficient for mismatch repair. CIN CRC show several forms of 
genomic instability, characterized mainly by chromosomal rearrangements and 
numerical abnormalities at a greatly increased rate compared with normal cells. The 
most recurrent aberration found in all cytogenetic studies performed, either in primary 
tumors or in colon cancer cell lines or in fixed colorectal cancer tissue blocks is 18q 
(Figure 3). (see the review by Migliore et al., 2011). 
 
Figure 3: The most frequent aberrations found in CRC (Migliore et al., 2011). 
 
 
 
 
1.4 Epigenetics 
 
Epigenetics is defined as heritable changes in gene expression that are not accompanied 
by changes in DNA sequence. An epigenetic modification is DNA methylation, a 
covalent addition of a methyl group (CH3) to the nucleotide cytosine. In mammals, 
most of the DNA CpG sites are methylated (90%–98%), but there are specific CpG-rich 
areas of DNA where most CpGs are not methylated (CpG islands); a few genes are 
imprinted genes, regulated by methylation of the CpG islands in their promoter, and the 
markings are stably replicated during cell division, but are reversed when inherited 
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through an individual of the opposite sex. CpG islands are associated with promoter 
regulatory regions of almost all housekeeping genes as well as with half of tissue-
specific genes (Esteller et al., 2011). Promoter hypomethylation has been associated 
with an increased gene transcription. DNA hypermethylation occurs at specific 
regulatory sites in the promoter regions or repetitive sequences. A heavy density of 
cytosine methylation in the CpG islands of the tumor suppressor gene promoters can 
lead to a complete block of transcription, and many types of cancer use this mechanism 
to inactivate tumor suppressor genes. Another critical epigenetic mechanism refers to 
chemical modifications of the histone tails. Histones, besides being DNA-packaging 
proteins, can regulate the underlying DNA sequences through complex posttranslational 
modifications of their N-terminal tails, such as aminoacid-specific acetylation, 
methylation, or phosphorylation. Histones are acetylated on lysine residues at their 
amino termini by histone acetyltransferases (HATs), and acetylated histones are 
deacetylated by HDACs. The opposing effects of HATs and histone deacetylases 
(HDACs) regulate gene expression through chromatin modification. The HDAC-
mediated removal of acetyl groups from lysine residues in the amino termini of histones 
leads to chromatin condensation and transcriptional inactivation of the involved DNA 
(Ropero et al., 2007; Yang et al., 2007). This transcriptional inactivation can contribute 
to suppression of tumor suppressor gene expression and enhanced tumorigenesis. Non-
coding RNA (ncRNAs) are involved in the regulation of many important biological 
processes; the most widely studied class of ncRNAs are miRNAs, which are involved in 
post-transcriptional gene silencing by controlling mRNA translation into proteins. 
Alterations (genetic or epigenetic) of genes coding these ncRNAs can modify the 
expression profile of the ncRNAs and thus alter the mechanism they regulate. 
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1.4.1 DNA methylation in colorectal cancer 
Almost 30–40% of proximal site colon tumors and a 3–12% of distal colon and rectal 
tumors are characterized by a high CIMP, in which numerous CpG islands are 
methylated and several tumor suppressor genes or ncRNA are inactivated. Altered 
promoter DNA methylation seems to correlate with deregulation of DNA 
methyltransferases. De novo DNA methyltransferase 3B (DNMT3B) is generally 
repressed in human colorectal cancer cell lines (CCL) and primary tumors by aberrant 
DNA hypermethylation of its distal promoter. DNMT3B distal promoter region was 
unmethylated in nomal colon tissue and densely hypermethylated in certain colon 
cancer cell lines. The CpG sites located 764 bp upstream and 208 downstream the TSS 
(transcription start site) were hyper-and hypomethylated respectively and showed no 
differences between healthy and tumor samples. The CpG site 352bp upstream of the 
TSS was completely unmethylated in non–tumorigenic colon tissues, while it was 
hypermethylated to different degree in most colon CCL analyzed (HCT15, Sw480, 
Co115, HT29). None of the tumors overexpressing DNMT3B showed DNMT3B 
promoter hypermethylation. 25% of primary colon tumors with an unmethylated 
DNMT3B promoter overexpressed DNMT3B. At the epigenome level, DNMT3B 
promoter hypermethylation was associated with the hypomethylation of gene promoters 
usually hypermethylated in the healthy colon. Forced DNMT3B overexpression in 
cancer cells restored the methylation levels of these promoters in the healthy colon 
(Huidobro et al., 2012). Some genes such as hLMH1, MGMT and TSP1 showed an 
increase in methylation during all the stages of the disease. Other genes such as 
RASSF1A or TIMP3 seem more methylated in the last stages or in metastases. However, 
sometimes conflicting results are found, with the same gene studied. This could be 
because of the analysis of different CpG sites in the same gene depending on the 
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different methods used to assess methylation [Pyrosequencing, vs Methylation Specific 
Polymerase chain reaction or vs COBRA]. Moreover, differences in age, tumor type or 
heterogeneity, or different exposure to environmental factors (diet or microorganisms) 
could also explain the contrasting methylation pattern of specific genes found in various 
studies. Leong and co-workers (Leong et al., 2011) found an inverse relationship 
between methylation of 10 tumor suppressor genes and chromosomal aberrations; then 
if the frequency of methylation is less prevalent in advanced disease, it is possible that 
the advanced rectal cancers are driven via the CIN pathway, whereas the early cancers 
were driven via the methylation pathway. Some genes could have a dual role to promote 
or suppress tumor formation depending on tumor type and molecular context; the 
receptor tyrosine kinase-like orphan receptor 2 (ROR2), a transmembrane protein that 
participates in Wnt signaling, is frequently silenced by promoter hypermethylation in 
human colon cancer; instead in osteosarcoma cells suppressed expression of ROR2 
inhibits cell invasiveness (Lara et al., 2010). SPARCL1 protein was over-expressed in 
the early stages and weakly expressed in the metastatic tumors; however, in a study of 
non-small cell lung carcinoma, SPARCL1 mRNA levels were found to be down-
regulate. SPARCL1 protein could therefore play a dual role of oncogene in colorectal 
carcinoma and tumor suppressor in lung cancer (Zhang et al., 2011). The discovery of 
methylation marks in CRC was considered of fundamental importance to correlate 
methylation status of specific genes with early diagnosis and prognosis. For instance, it 
was shown that aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes is 
associated to tumor initiation, but not to tumor progression (Lee et al., 2009). Several 
epigenetically silenced genes have an important role in colorectal carcinogenesis; 
APC2, a homolog of APC1 tumor suppressor gene involved in Wnt signaling pathway, 
showed a frequency of 95.5% methylation in its promoter. ECAD, a Ca+-dependent 
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adhesion molecule that mediates intercellular contacts, was hypermethylated in 40.8% 
of primary CRCs. Loss of ECAD expression is then associated with the invasion and 
metastasis (Naghibalhossaini et al., 2011). Lind and colleagues (Lind et al., 2011) 
found promoter hypermethylation of the CNRIP1, FBN1, INA, MAL, SNCA, and SPG20 
genes was frequent in both CRCs (65–94%) and adenomas (35–91%), whereas normal 
mucosa samples were rarely (0–5%) methylated; the sensitivity of at least two positives 
among the six markers was 94% for CRCs and 93% for adenoma samples, with a 
specificity of 98%. Methylation of IGFBP3, EVL, FLNC, and CD109 genes is 
associated with an eightfold increase in mortality risk relative to that of patients with no 
DNA methylation of these genes (Carmona et al., 2011). Moreover, hypermethylation 
of CDH13 and FLBN3 genes is associated with poor prognosis in CRC (Wang et al., 
2011). Looking for novel prognostic biomarkers for CRC, recent studies showed that 
tumors that have silenced genes in the extracellular matrix remodeling pathway show 
worse survival (Carmona et al., 2011; Yi et al., 2011). Invasive screening modalities, 
including colonoscopy, are not ideal for application to the asymptomatic population. 
Therefore, active investigations are now underway to discover noninvasive biomarkers, 
such as those found in stool, which could supplement or supplant colonoscopic 
screening. DNA methylation changes have also been observed in plasma as a marker of 
circulating tumor DNA. Less is known about changes in WBC DNA methylation levels 
and cancer risk, although studies are rapidly emerging. Several studies measuring 
overall WBC global DNA methylation in different cancer types including colon, 
bladder, stomach, breast, head and neck cancer have found an elevated risk (sometimes 
statistically significant) for cancer between those in the lowest quantile of global DNA 
methylation compared to those in the highest quantile (Terry et al., 2011). In plasma, 
cell-free methylated DNA AQ3 has been reported to be a useful biomarker of 
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noninvasive blood screening for the detection of CRC. Septin 9 (SEPT9) and vimentin 
(VIM) genes have been analyzed in blood/serum samples and stool samples and 
reported sensitivity and specificity range of 68–77% and 83–94%, respectively (Chen et 
al., 2005; Devos et al., 2009). Among genes that have been proven to be promising for 
an early diagnosis of CRC, besides SEPT9 (Grützmann et al., 2008), there are also 
ALX4 and TMEFF2 (He et al., 2010). Loss of SMAD4, a tumor suppressor gene 
frequently inactivated in pancreatic and CRCs, correlates significantly with decreased 
survival in colon cancer patients. High SMAD4 expression, however, is significantly 
associated with increased survival, especially in colon cancer patients who has 
undergone potential curative surgery (Isaksson-Mettävainio et al., 2011). Figure 4 
shows some genes methylated during the different stages of carcinogenesis and figure 5 
shows the most studied genes which have been found methylated in CRC, with their 
possible functions in cancer initiation and progression.  
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Figure 4: Methylation of genes during CRC stages  (Migheli and Migliore, 2012).  
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proximal  tumor site (PYROSEQUENCING)  (Gay et al., 2011) 
hMLH1 (all methylation negative samples with less then 20% of methylation); PYROSEQUENCING assay (Gay et al., 2011)
hMLH1, hMSH2 and MGMT respectively  methylated in  1.8%, 8.0%, 33.9% of salmples; MSP  assay  (Lee et al.,  2011 ) 
hMLH1,  hMSH2, MGMT (respectively  methylated in  0%, 5.4%,  10.7% of samples); MSP assay (Lee et al.,  2011 ) 
hMLH1, MSH2, MGMT (respectively  methylated in 1,8%, 13.4% and  47.3%  of samples; MSP (Lee et al.,  2011 ) 
The highest methylation detected was for MGMT gene (47.1%) followed by 35.3% for HIC-1 and 5.9% for RASSF1A gene; 
MSP assay (Abouzeid et al., 2011)
High frequency of methylation at MGMT, RASSFA, and HIC-1 (respectively  in 25%, 47.2%, and 41.7% of samples);
MSP assay (Abouzeid et al., 2011).
67% of samples  had methylation in EVL/hsa-miR-342; MSP assay  (Grady et al., 2008) 
86% of samples  methylated in EVL/hsa-miR-342; MSP assay  (Grady et al., 2008)
Methylated EVL/hsa-miR-342 in 12% of normal mucosa from cancer-free controls and  56% of histologically
normal colorectal mucosa from individuals with concurrent colorectal adenocarcinoma (‘ﬁeld defect’); 
MSP assay  (Grady et al., 2008) 
Extensive (including  two methylation-sensitive regions) and partial (one of two regions) SFRP2 methylation levels found in 61.7% and 
24.8% of samples; COBRA (Takeda et al., 2011) .
Extensive (including  two methylation-sensitive regions ) and partial (one of two regions) SFRP2 methylation levels were in
8.7 % and 37.9 % of samples; COBRA (Takeda et al., 2011) .
Extensive (including  two methylation-sensitive regions ) and partial (one of two regions) SFRP2 methylation levels were in 3.9 % 
and 39.9 % of normal colonic mucosa from CRC patients (N-Cs), and in 0 % and 30.6 % of colonic mucosa from subjects with no 
evidence of colorectal neoplasia at colonoscopy; COBRA (Takeda et al., 2011) .
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Figure 5: The methylation pattern of many genes from normal and tumor colonic mucosa from CRC 
patients has been extensively studied. Here we report the most studied genes and the pathways in which 
they are involved (Migheli and Migliore, 2012). 
 
 
 
1.4.2 Histone modifications in colorectal cancer 
Little is known about patterns of histone modification alteration in human tumors and 
even less in CRC. Chromatin remodeling is, together with methylation, a key 
mechanism for gene regulation and consists of modifications at conserved lysine 
residues on the tails of histone proteins; lysine acetylation allows the transcription by 
weakening the association of the histone with DNA and allows transcription factor 
binding. Lysine methylation can be associated with both active and repressed regions of 
DNA; trimethylation of histone H3 lysine 4 active transcription, instead methylation of 
H3K9 and H3K27 appears at transcriptionally silent gene promoters (Jones et al., 
2007). Hypomethylation alone cannot turn on silenced genes, instead increased Histone 
H3 acetylation with localized hypomethylation allows long-term reversion of 
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epigenetically silenced genes; a study showed as CDO1, HSPC105 and MAGEA3 were 
still expressed 10 days post 5-aza-dC treatment, in fact they had localized 
hypomethylation at the transcriptional start site and an increased histone H3 acetylation 
(Mossman et al., 2011). Enzymes for chromatin remodeling can alter chromatin by 
covalent modification of histone or by using the energy from ATP hydrolysis. Included 
in the ATP-dependent chromatin remodeling enzyme family is the chromodomain 
helicase DNA-binding protein (CHD) family, which consists of nine proteins (CHD1–
9) in humans. With regard to cancer, CHD5 controls proliferation and apoptosis. In 
humans, CHD5 is inactivated not only by deletion but also by hypermethylation. These 
alterations might contribute to cancer pathogenesis by deregulating CHD-mediated 
chromatin remodeling (Kim et al., 2011). SOCSs and SHP1 genes seem to have a role 
as tumor suppressor and DNA methylation as well as histone acetylation/deacetylation 
could control their transcriptional regulation in CRC cells. Xiong and colleagues (Xiong 
et al., 2012) showed that TSA, an histone deacetylase inhibitor (HDACi), increased the 
mRNA levels of SOCS1 and SOCS3. The induction of SOCS1 and SOCS3 expression 
by TSA in human CRC cells was because of an increase in the acetylation of H3 and H4 
histone proteins associated with their promoter regions. However, they did not observe 
any significant changes in histone acetylation of SHP1 promoter regions. Two different 
studies reported that the global levels of H4K12ac and H3K18ac increased in 
adenocarcinomas respect to the normal tissue or adenomas and that the H3K9me2 
expression was also associated with the progression adenoma–adenocarcinoma 
(Ashktorab et al., 2009; Nakazawa et al., 2011). 
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1.4.3 NcRNA alterations in colorectal cancer 
 Chromosome anomalies (deletions, translocations, copy-number alterations), DNA 
mutations and epigenetic deregulation of the ncRNAs or of the genes involved in their 
biogenesis have been described in tumor progression and the best-characterized 
miRNAs dysregulated by DNA hypermethylation in tumors, including CRC and the 
functional consequences in tumoral cells, have been reviewed recently (Lopez-Serra et 
al., 2011). In Table 2 some recent examples of ncRNAs found dysregulated in CRC 
cells are shown. For instance, epigenetic alteration of miR-143 which targets KRAS can 
interfere with its expression and induce cell proliferation (Liu et al., 2010); epigenetic 
alteration of miR-148b which targets cholecystokinin-2 receptor gene (CCK2R) can 
lead to cell proliferation (Song et al., 2011). A small part of the miRNAs were up-
regulated by 5-aza-2 deoxycytidine (5-aza-dC) treatment in CRC cells; however, 
different cell type like SW1116 and HT29 cell could have different drug sensitivity. 
DNA methylation analyses showed that the promoter region of the mir-345 gene was 
heavily methylated in HT29 cells (64.73%) and it was decreased to 35.78% after 5-aza-
dC treatment, which results in a major mir-345 expression; AQ4 overexpression of mir-
345 may suppress colon cancer cell invasiveness in vitro. mir-345 might be involved in 
pathogenesis of CRC through downregulation of the expression of BAG3, one of the 
molecules that regulates apoptosis (Tang et al., 2011). Hox transcript antisense 
intergenic RNA (HOTAIR) is a long ncRNA that regulates expression of multiple genes 
in cooperation with PRC2; HOTAIR expression levels in CRC tissues were higher than 
those in corresponding noncancerous tissues; its overexpression increased the 
invasiveness of CRC cells, then this ncRNA might play a role in promoting metastasis 
of CRC. Moreover, patients with high HOTAIR expression had a significantly poorer 
prognosis than those with low HOTAIR expression (Kogo et al., 2011). 
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Table 2: Deregulation of ncRNAs in CRC by epigenetic, chromosome abnormalities (deletions, 
translocations, copy-number alterations), and DNA mutations (Migheli and Migliore, 2012). 
 
 
1.5 Colorectal adenoma-carcinoma sequence  
 
An unresolved question related to genomic instability, which has been raised in many 
papers, is whether CIN arises early in tumorigenesis and initiates the adenoma-
carcinoma sequence or whether it is acquired during this process and facilitates the 
formation of colon cancer. Michor et al. developed a mathematical representation of the 
evolutionary dynamics of colorectal tumorigenesis and found that one or two CIN genes 
in the genome are enough to make sure CIN emerges early (Michor et al., 2005). 
However this view is not universally accepted: some authors are inclined to believe that 
CIN is acquired during tumorigenesis and facilitates progression to malignancy. Even in 
light of the latest knowledge, the question is still considered unresolved (see the recent 
review by Pino and Chung, 2010). Different tumors show various patterns of 
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aneuploidy. The loss of heterozygosis that occur in the first phases of the CRC 
cancerogenesis, as well as the alteration of methylation pattern of multiple key genes 
can drive the development of colorectal cancer by facilitating the acquisition of multiple 
tumor-associated mutations and the instability phenotype. Aberrant CpG island 
methylation is involved in cancer development, but it is not yet clear if it is a cause or 
an effect of cancer formation, which genes are methylated during the pathogenesis of 
individual cancers, when is the time of methylation and gene silencing, how specific 
methylation profiles are established, and what determines tumor typespecific 
methylation (Kim et al., 2010). Restricted folate diet or SNPs in one-carbon 
metabolism, leading to a reduction of the total amounts of DNA methylation in human 
tumors results in hypomethylation of repetitive DNA sequences, contributing to the 
origin of cancer cells by generation of chromosomal instability, reactivation of 
transposable elements, and loss of imprinting; moreover, hypomethylation could 
activate proto-oncogenes. The misincorporation of uracil into human DNA, favoured 
when thymidylate availability is restricted, could also increase the frequency of 
chromosome cleavage. On the other hand, tumor suppressor genes could gain CpG 
island methylation, resulting in the inactivation of these protecting proteins. Moreover 
epigenetic alterations could influence either cancer initiation or progression. In 1990 
Fearon and Volgestein proposed a model for colorectal tumorigenesis. For this model 
the mutational activation of oncogenes and inactivation of tumor suppressor genes, lead 
to the development of CRC. These alterations generally occur in a vertical sequence that 
goes togheter with the clinical progression of the tumor, but probably it is more 
important the total accumulation of changes rather than their order. The key oncogene 
in this model is K-RAS, instead the tumor suppressor genes involved reside on 
chromosome 5q, 17p and 18q. Other somatic alterations, such as DNA methylation, are 
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involved (Leslie et al., 2002). Figure 6 shows a colorectal adenoma-carcinoma sequence 
model. 
 
 
Figure 6: Colorectal adenoma-carcinoma sequence (according to Fearon and Volgestein model). 
 
 
 
 
1.5.1 APC (Adenomatous Polyposis Coli) gene 
The human APC  gene is located on the long (q) arm of chromosome 5 between 
positions 21 and 22, from base pair 112,118,468 to base pair 112,209,532. 
 
This gene encodes a tumor suppressor protein that acts as an antagonist of the Wnt 
signaling pathway.  It is also involved in other processes including cell migration and 
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adhesion, transcriptional activation, and apoptosis. Defects in this gene cause familial 
adenomatous polyposis (FAP), an autosomal dominant pre-malignant disease that 
usually progresses to malignancy (see page 5). Disease-associated mutations tend to be 
clustered in a small region designated the mutation cluster region (MCR) and result in a 
truncated protein product. APC activity is correlated with its phosphorylation state. The 
APC gene product (2843 amino acids; 310 kDa) indirectly regulates transcription of a 
number of critical cell proliferation genes, through its interaction with the transcription 
factor β catenin. APC binding to β catenin leads to ubiquitin-mediated beta catenin 
destruction; loss of APC function increases transcription of β catenin targets. These 
targets include cyclin D, C-myc, ephrins and caspases. Particularly the APC protein 
normally builds a complex with glycogen synthase kinase 3-beta (GSK-3β) and axin. 
This complex is then able to bind β- catenin in the cytoplasm; with the help of casein 
kinase 1 (CK1), which carries out an initial phosphorylation of β-catenin, GSK-3β is 
able to phosphorylate β-catenin a second time. This targets β-catenin for ubiquitination 
and degradation by cellular proteosomes. This prevents it from translocating into the 
nucleus, where it acts as a transcription factor for proliferation genes. APC also interacts 
with numerous actin and microtubule associated proteins. APC itself stabilizes 
microtubules. Hypermethylation of APC promoter 1A, instead of mutations involving 
APC and beta-catenin, contributes to moderate activation of Wnt signalling in a subset 
of serrated adenomas (Fu et al., 2009). A study analyzed the methylation status of 10 
genes in fresh-frozen tissues and corresponding plasma samples from  patients from 
stage I and II of sporadic colorectal cancer, 276 healthy individuals, and plasma from 64 
colorectal adenoma patients using MSP. The methylation was detected in 18% for p14, 
34% for p16
Ink4A
, 27% for APC, 34% for DAPK, 32% for HLTF, 21% for hMLH1, 39% 
for MGMT, 24% for RARbeta2, 58% for RASSF2A, and 74% for Wif-1; the author 
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concluded that tumor-specific methylation of APC, MGMT, RASSF2A, and Wif-1 genes 
might be a valuable biomarker in plasma for the early detection of CRC (Lee et al., 
2009). 
 
1.5.2 MGMT (O-6-methylguanine-DNA methyltransferase) gene 
Cytogenetic Location 10q26.3: Start: 131,265,448 bp from pter - End: 131,566,271 bp 
from pter;  Size: 300,824 bases. Protein: 207 amino acids; 21646 Da.  
 
O(6)-alkyl-guanine is the major carcinogenic lesion in DNA induced by alkylating 
mutagens. This DNA adduct is removed by the repair protein, O(6)-methylguanine-
DNA methyltransferase. This protein is not a true enzyme since it accepts the alkyl 
group from the lesion in a stoichiometric reaction and the active enzyme is not 
regenerated after it is alkylated. The methyl-acceptor residue in the protein is cysteine. 
MGMT promoter methylation in normal colonic mucosa might be a predisposing factor 
for cancer as a field effect and an early event in colorectal carcinogenesis. MGMT 
promoter methylation and loss of expression have been associated with G>A mutations 
in a variety of genes such as KRAS, PIK3CA, TP53, and APC (Halford et al. 2005; Shen 
et al., 2005; Ogino et al. 2007; Nagasaka et al., 2008; Nosho et al. 2008). DNA 
hypermethylation for hMLH1 and MGMT DNA repair genes was reported in precursor 
lesions to colorectal cancer. These epigenetic alterations may be influenced by factors 
such as xenoestrogens, folate, and multivitamins. Detection of these changes may help 
determining cancer susceptibility and early diagnosis (Dumitrescu, 2012). Promoter 
hypermethylation status of RASSAF1A, MGMT, and HIC-1 genes were determined in 
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36 CRC, 17 adenomatous polyps, and 19 ulcerative colitis, and adjacent normal-
appearing tissues using MSP assay. High frequency of methylation at MGMT, 
RASSF1A, and HIC-1 genes was detected in CRC patients (25%, 47.2%, and 41.7% 
respectively). The highest methylation observed in adenomatous polyps patients was in 
MGMT gene (47.1%) followed by 35.3% for HIC-1 gene and only 5.9% for RASSF1A 
gene; they also found an association between methylation at RASSF1A gene with gender 
(p = 0.005) (Abouzeid et al., 2011). Morning stool specimens were collected from 69 
patients with colorectal cancer, 24 with colon adenoma, 19 with hyperplastic polyps, 
and 26 healthy controls. The methylation frequencies of MAL, CDKN2A and MGMT 
were 78.3%, 52.5% and 55.1% in colorectal cancer, 58.3%, 41.7% and 37.5% in colon 
adenomas, 26.3%, 15.8% and 10.5% in hyperplastic polyps, and 3.8%, 0 and 3.8% in 
healthy controls, respectively. Significant differences in three genes were found 
between colorectal cancer and hyperplastic polyp, colorectal cancer and healthy control, 
colon adenoma and hyperplastic polyp, colon adenoma and healthy control (all P<0.05). 
The diagnostic sensitivity by combining three methylation markers was 92.8% in 
colorectal cancer, 70.8% in colon adenomas, significantly higher than fecal occult blood 
test (29.0% in colorectal cancer and 25.0% in colon adenomas, all P<0.05). No 
significant associations existed between methylation of the three genes and clinical 
characteristic including sex, age, tumor location, lymphnode metastases and TNM stage 
(all P>0.05) (Kang et al., 2011). A study showed an association (81%, κ = 0.59, p < 
0.0001) between MGMT methylation and MGMT loss. MGMT methylation and loss of 
MGMT were not perfectly correlated; in fact MGMT expression may be caused not only 
by promoter methylation but also by other mechanisms such as a gene mutation. 
Second, promoter methylation may be present in only one MGMT allele, and the 
MGMT protein may be expressed from the second allele. Third, there may be other 
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molecules such as ncRNA, that may downregulate MGMT (Shima et al., 2011). It was 
hypothesised that an MGMT field defect may constitute a preneoplastic event for the 
development of MMR-deficient tumors displaying microsatellite instability (MSI). Loss 
of MGMT expression was more frequent in MSI than MSS CRC (p=0.047); moreover 
loss of MGMT expression was associated with MGMT gene promoter methylation 
(p=0.03) (Svrcek et al., 2010). Methylation status of the MGMT gene was examined in 
primary carcinomas and the corresponding normal tissues in 48 patients with CRC 
using MSP; aberrant methylation was detected in 21% of primary colorectal cancers. 
There was no statistically significant association between abnormal methylation and 
gender or age, maximal tumor size, tumor extent, tumor site, histology, lymphnode 
metastasis, and TNM stage. All stages of colorectal cancers presented MGMT 
methylation, indicating that the MGMT gene has been methylated from the early stages 
of colorectal cancers (Hibi et al., 2009). A study observed the incidence of MGMT 
methylation increased along the adenoma–carcinoma sequence, and the evaluation of 
the contribution of MGMT methylation to the development of an advanced lesion was 
statistically significant. The increased incidence of MGMT methylation in normal-
appearing mucosa could represent the “field defect”. Authors reported that MGMT 
promoter methylation occurred frequently in the apparently normal colonic mucosa of 
CRC patients with tumors that also showed MGMT promoter methylation; in contrast, 
MGMT promoter methylation was observed much less frequently in healthy subjects 
and in the apparently normal colonic mucosa of CRC patients with tumors that did not 
show MGMT methylation. In addition, they observed an association between age and 
promoter methylation levels. Methylation detected by MSP may not affect the 
expression of gene products if methylation affects only a few cells or if the methylation 
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of one copy happens with an absence of methylation in the other copy of the gene (Lee 
et al., 2011). 
 
1.5.3 CDKN2A or p16
Ink4A
 (Cyclin-dependent kinase inhibitor 2A) gene 
Cytogenetic Location 9p21.3: Start: 21,967,751 bp from pter- End: 21,995,300 bp from 
pter; Size: 27,550 bases. 
 
This gene generates several transcript variants which differ in their first exons. At least 
three alternatively spliced variants encoding distinct proteins have been reported, two of 
which encode structurally related isoforms known to function as inhibitors of CDK4 
kinase. It acts as a tumor suppressor  and has to arrest the cell cycle in G1 and G2 
phases. It binds to MDM2 and inhibits its oncogenic action by blocking MDM2-
induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. 
It also induces G2 arrest and apoptosis in a p53-independent manner by preventing the 
activation of cyclin B1/CDC2 complexes. Increased expression of the p16
Ink4A
 gene 
reduces the proliferation of stem cells. This reduction in the division and production of 
stem cells protects against cancer while increases the risks associated with cellular 
senescence. Analysis of p16
Ink4A
 promoter methylation was performed by MSP assay. 
42.1% of the CRC were found to have the p16
Ink4A
 gene methylated. The methylation 
status was found to be associated with the gender, lymph node status, tumor stage, 
smoking status and tumor grade of the CRC patients. P16
INK4A
 plays a pivotal role in 
tumor development and progression to advanced stages (Sameer et al., 2012). P16
INK4A
 
methylation was evaluated by Q-MSP technique in the serum of CRC patients during 
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their follow-up period. The p16
Ink4A
 methylation decreased during two weeks after 
surgery. One month after surgery, in the patients with recurrence of cancer, a great 
increase in p16
Ink4A
 methylation was observed, while in the disease-free patients no 
methylation was seen more; so methylation could sensitively reflect the recurrence 
status and may be useful for identifying the presence of recurrence during the follow-up 
of CRC patients (Nakayama et al., 2011). Colorectal cancer (CRC) screening using 
stool DNA has yielded a greater detection rate than conventional fecal occult blood 
testing. Stool samples from 31 healthy controls, 25 patients with adenomas and 30 
patients with CRC were analyzed and methylation regard to ITGA4, SFRP2 and p16
Ink4A
 
promoters were observed in 36.7%, 60.0%, and 40.0% of the CRC samples and in 
16.0%, 44.0%, and 24.0% of the colorectal adenomas, respectively. The methylation 
status had high sensitivity and specificity for the detection of colorectal adenomas and 
CRC; thus stool screening might be a useful non-invasive method for CRC detection 
(Chang et al., 2010).  Aberrant methylation of p16
Ink4A
 and hMLH1 promoters was 
found in 47.2% and 53.4% of tumors respectively. For adjacent normal mucosa, 30% of 
patients were fully unmethylated in p16
Ink4A
 promoter, whereas hMLH1 promoter was 
predominantly unmethylated (76%). Methylation of p16
Ink4AI
 correlated with gender and 
tumor size, whereas that of hMLH1 significantly correlated with overall survival. 
Concomitant methylation of CDKN2A and hMLH1 genes was associated with TNM 
stage and tumor size (Miladi-Abdennadher et al., 2011). 
 
 
 
 
 30 
 
1.5.4 RASSF1A (Ras association (RalGDS/AF-6) domain family member 
1) gene 
 
Cytogenetic Location 3p21.31: Start: 50,367,217 bp from pter-End: 50,378,411 bp from 
pter; Size: 11,195 bases. 
Several alternatively spliced transcript variants of this gene encoding distinct isoforms 
have been reported. It is a potential tumor suppressor. Isoform A interacts with CDC20, 
an activator of the anaphase-promoting complex (APC
Cdc20
) that initiates chromatid 
separation and entrance into anaphase. The APC
Cdc20
 protein complex targets securin for 
destruction, enabling sister chromatid separation. It also targets S and M-phase (S/M) 
cyclins for destruction, which inactivates S/M cyclin-dependent kinases (Cdks) and 
allows the cell to exit from mitosis. Isoform A also disrupts interactions among MDM2, 
DAXX and USP7, thus contributing to the efficient activation of TP53 by promoting 
MDM2 self-ubiquitination in cell-cycle checkpoint control in response to DNA damage. 
MSP was used to examine the promoter methylation status of the serum RASSF1A gene; 
the RASSF1A promoter hypermethylation in gastric (34.0%) and colorectal (28.9%) 
adenocarcinoma patients were significantly higher than those in patients with benign 
gastric (3.3%) or colorectal (6.7%) disease or in healthy donors (0%) (P < 0.01). 
Although the serum RASSF1A promoter hypermethylation frequency tended to be 
higher in patients with distant metastases, there was no correlation between methylation 
status and metastasis. There was no correlation between serum RASSF1A promoter 
hypermethylation and sex, age, tumor differentiation grade, surgical therapy, or serum 
carcinoembryonic antigen level (Wang et al., 2008). A study analyzed, by mean of Q-
MSP, primary tumor and synchronous liver metastatic tissues of 75 CRC patients and 
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evaluated K-RAS and BRAF mutations. RARbeta, RASSF1A, and CDKN2A genes were 
methylated in 82%, 35%, and 26% of primary tumors, respectively. RASSF1A 
methylation status was significantly higher in liver metastasis with respect to primary 
tumor (P=0.000) underlying the role of this gene in liver metastatic progression. 
Moreover K-RAS and BRAF were mutated in 39% and 4% of cases, respectively and 
RASSF1A methylation resulted significantly higher in liver than in primary tumor 
(P=0.05) only in K-RAS wild-type patients. All Ras protein family members are 
GTPase; when RAS is 'switched on' by incoming signals, it subsequently switches on 
other proteins, which turn on genes involved in cell growth, differentiation and survival. 
As a result, mutations in RAS genes can lead to the production of permanently activated 
Ras proteins. This can cause unintended and overactive signaling inside the cell, even in 
the absence of incoming signals. Ras is the most common oncogene in human cancer; 
mutations that permanently activate Ras are found in 20-25% of all human tumors and 
up to 90% in certain types of cancer (Tommasi et al., 2011).  
 
1.5.5 hMLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) gene 
Cytogenetic Location: 3p21.3; from 37,034,840 to base pair 37,092,336; The hMLH1 
gene is composed of 19 exons spanning in a region of 57496 bp. Protein: Aminoacids: 
756. Molecular Weight: 84.6 kDa. 
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The MLH1 gene is a member of a set of genes known as the mismatch repair (MMR) 
genes. This protein fixes mistakes that are made during DNA replication in preparation 
for cell division. It contains an ATPase domain and two interaction domains, one for 
MutS homologs (MSH2, MSH3, MSH6) and the other for PMS2, MLH3 or PMS1. 
MLH1 has no known enzymatic activity. MLH1 forms a heterodimer with PMS2 
known as MutLa, although it can also bind to PMS1 or MLH3. This heterodimeric 
complex binds to the heteroduplexes MutSa (composed of MSH2 and MSH6) or MutSb 
(composed of MSH2 and MSH3), which recognizes DNA lesions. The heterodimer 
formed by MLH1 is responsible for the recruitment of the proteins needed for the 
excision and repair synthesis. The repair is made by removing a section of DNA that 
contains mistakes and replacing the section with a corrected DNA sequence.  A study 
evaluated the frequency of promoter methylation for hMLH1, hMSH2, and MGMT in 
colorectal non-tumoral mucosa adenoma, and adenocarcinoma by mean MSP assay. 
The hMLH1 promoter was methylated in 1.8% of the adenoma and adenocarcinoma 
samples. No methylation of hMLH1 was found in any corresponding non-tumoral 
mucosa tested. MSH2 promoter methylation was found in 8.0% of adenoma and 13.4% 
of adenocarcinoma samples. MGMT methylation was detected in 33.9% of adenoma 
and 47.3% of carcinoma samples. In the corresponding normal-appearing mucosa, 
methylation was seen in hMSH2 (5.4%) and MGMT (10.7%), but not in hMLH1 (Lee et 
al., 2011). In other study by Psofaki et al. (2010) promoter hMLH1 hypermethylation 
was observed in tumor samples, but not in blood samples. 
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1.6 Environmental factors that might influence epigenetic patterns in 
colorectal cancer. 
Studies where people migrate from low to high CRC risk areas of the world, 
demonstrate that changes of diet and physical activity enhance the incidence of cancer 
in a high-risk country even over one or two generations (Nystrom et al., 2009). 
Considering CpG island methylation levels in normal colorectal mucosa of different 
racial groups, some Authors found that African Americans had lower levels of 
methylation compared to Caucasians and Hispanics. Possible explanations for these 
findings, include lifestyle factors, genetic protection or predisposition to methylation 
(Wallace et al., 2010). Moreover, monozygotic twins carriers of high penetrant genetic 
alteration in HNPCC, associated with hMLH1 mutations, develop cancer at different 
ages. These observations suggest a role of the environment in epigenetic changes 
(Esteller et al., 2008).  
 
It was observed that a positive association between vitamin B6 and rectal cancer risk 
exists in women. Among men, methionine was associated with a decreased risk of 
proximal colon cancer whilst among women it was inversely associated with rectal 
cancer (De Vogel et al., 2008).  
Choline could derive from the diet, but also from de novo biosynthesis by means of an 
enzyme coded by the gene phosphatidylethanolamine-N-methyltransferase (PEMT). 
One of the choline metabolites, betaine, participates in the methylation of homocysteine 
to form methionine. Then choline and betaine have been hypothesized to decrease the 
risk of colorectal cancer. Estrogens cause a marked upregulation in PMET mRNA 
expression and enzyme activity, then premenopausal women have an enhanced capacity 
for de novo biosynthesis of choline. In choline deficient cells in culture, and in fetal 
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rodent brains from mothers fed with choline-deficient diets, methylation of the CDKN3 
gene promoter decreased, resulting in overexpression of this gene which inhibits cell 
proliferation. Maternal diet high in choline and/or methionine and/or methyl-folate 
during pregnancy results in epigenetic changes in gene expression in the fetus (Zeisel et 
al., 2007). 
 
Alcohol consumption was found to be a risk factor for colorectal tumorigenesis. In an in 
vivo study (male rats), it was observed that a decrease in RFC1 (reduced folate carrier) 
mRNA and protein expression correlates with alcoholism. That is a possible reason of 
lower blood folate levels commonly found in chronic alcoholics (Hamid et al., 2009). 
Alcohol in murine studies appears to reduce MTR levels; thus it could induce DNA 
hypomethylation (Arasaradnam et al., 2008). Alcohol consumption may in fact decrease 
DNA methylation in hepatic tissue by affecting folate metabolism and/or methionine 
synthesis, which might decrease levels of the S-adenosylmethionine (SAM), the main 
methyl donor of DNA. Excessive alcohol consumption has been shown to alter DNA 
methylation in humans. Patients suffering from alcoholism had 8–10% higher 
methylation in CCGG sequences respect to controls. Associations between alcohol 
drinking and DNA repetitive element methylation levels have shown inverse 
associations between Alu and alcohol drinking. However, several studies did not find an 
association between alcohol consumption and LINE1 methylation. One study found a 
significant increase in HERP (homocysteine-induced ER protein) promoter methylation 
in patients with alcohol dependence (Terry et al., 2011). Moreover in a Dutch study, 
higher frequency of promoter methylation of APC1A, P14, hMLH1, MGMT, and 
RASSF1A genes was observed in presence of a low-folate/high-alcohol diet.  
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Tobacco could also influence CRC risk. The methylation levels for MGMT, RAR-b, and 
SST decrease in the following sequence: nonsmokers without colorectal adenomas > 
smokers without colorectal adenomas > nonsmokers with colorectal adenomas > 
smokers with colorectal adenomas. Smoking predisposes to diminished methylation of 
several genes, which, in turn, contribute to colorectal adenoma development (Paun et 
al., 2010). A study reported that the risk of CIMP-high tumor, among smokers of 20 or 
more cigarettes per day, was higher among those with low folate and low fiber intake 
and those who had greater long-term alcohol consumption, although without statistical 
significance. Moreover, among women alcohol and cigarette smoking were associated 
with risk of CIMP-high tumors; women who smoked 20 or more cigarettes per day and 
consumed little or no alcohol did not have an increased risk of a CIMP-high tumors 
(Slattery et al., 2007). The cellular modifications due to exposures to the chemicals 
present in cigarette smoke have been widely investigated and include DNA adducts, 
gene mutations, micronuclei, chromosome aberrations, sister chromatin exchanges and 
DNA strand breaks; DNMTs seem to bind DNA damage sites, which results in altered 
methylation patterns on these regions, suggesting a molecular mechanism for the 
generation of aberrant DNA methylation by exposure to chemicals such as those present 
in cigarettes. Only a few studies have investigated overall 5-mC content and smoking, 
and found no difference by cigarette smoking patterns. More research has focused on 
the effect of smoking on the methylation levels of repetitive elements. LINE-1, Alu and 
AluYb8 methylation did not differ between current and never/former smokers. It has 
been suggested that chemicals affecting epigenetic marks could have a larger impact 
when exposure occurs in utero or earlier in life, a time when epigenetic modifications 
are being established. Overall levels of genomic DNA methylation have been 
investigated in several studies in children and adults. Prenatal exposure to cigarette 
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smoke has been associated with an increase in the overall blood levels of DNA 
methylation in adulthood. LINE-1, Sat2 and Alu methylation was analyzed in adults and 
children prenatally exposed to smoking. LINE-1 and Sat2 levels were lower in exposed 
individuals when compared to unexposed ones. However, other elements such as LINE-
1 do not seem to be affected by exposure to cigarette smoke. Several genes were 
investigated in blood samples from adults in a cohort of individuals born preterm that 
were exposed to smoking, with lower levels found for IGF2 methylation (see review by 
Terry et al., 2011).  
 
In a study in vitro on HT 29 cells, green tea was found to inhibite DNMT1 causing CpG 
demethylation and reactivation of previously methylated genes (hMLH1, MGMT, 
P16
INK4A
). There is strong evidence that polyphenols from tea, soft fruits and berries, 
vegetables, apples, and even from wine, are potent anti-carcinogenic agents in vitro and 
in animal models that prevent DNA instability. Several polyphenols are potent 
inhibitors of DNMT activity in vitro, capable of reversing DNA hypermethylation and 
reactivating tumor suppressor genes activity. Polyphenols inhibit DNMT activity and 
DNA methylation in two ways: by direct insertion into the binding pocket of DNMT 
(competitive inhibition) or indirectly by decreasing intracellular SAM concentrations. 
Tea components (especially green and black tea) and specific soya isoflavones inhibit 
DNMT activity in human cancer cells. DNMT 1 inhibition demethylates CpG islands in 
the promoter regions of silenced tumor suppressor genes including p16
Ink4A
, retinoic 
acid receptor b, MGMT, mMLH1 and GST. Green tea (EGCG) can reactivate retinoic 
acid receptor b in prostate and breast cancer cells, p16
Ink4A
 in colon cancer cells and 
GST in prostate cells. Genistein could reverse DNA hypermethylation and reactivate 
p16
Ink4A
, retinoic acid receptor b and MGMT gene expression (Duthie, 2011). 
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Also selenium suppressed aberrant DNA methylation by means of DNMT inhibition 
(Arasaradnam et al., 2008).  
 
Arsenic has been associated with gene-specific hypermethylation of p53 and p16
Ink4A
 
promoter regions in blood DNA of subjects exposed to toxic level of arsenic compared 
to controls. Hypermethylation of the p16
Ink4A
 promoter was also observed in WBC DNA 
from 103 patients with arseniasis compared to 110 healthy subjects (see review Terry et 
al., 2011). 
 
Fiber intake reduces CRC risk, with dilution of fecal potential carcinogens, promoting a 
favorable colonic microflora, by adsorption of bile acids and by production of 
protective short-chain fatty acids (SCFAs principally acetate, propionate, and butyrate) 
through fermentation by endosymbiotic bacteria. Butyrate is a potent inhibitor of 
histone deacetylases (HDACs); reduced levels of butyrate will cause alterations in 
global protein acetylation, which may be permissive for colorectal cancer progression, 
while elevation of fibre levels and consequent butyrate levels may reduce or reverse 
these processes and restore a “normal” profile of protein acetylation. Acetyl proteins 
identified are nuclear structural proteins, transcription factors including p53, Sp1, and 
Sp3, and structural proteins including tubulin and cytokeratins (Corfe et al., 2009). 
Higher dietary fiber assumption was associated with reduced risk of having a CIMP-
high tumor (Slattery et al., 2007).  
 
DNA methylation has been also hypothesized as being a consequence of inflammation. 
Prostaglandins, that promote inflammation and fever, are produced within the body 
cells by the enzyme cyclooxygenase (COX). Nonsteroidal anti-inflammatory drugs 
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(NSAIDs) block the COX enzymes and reduce prostaglandins throughout the body, 
then their assumption has been hypothesized to be associated with development of 
colon tumors that display CIMP. Physical activity and use of NSAIDs were inversely 
associated with both CIMP-low and CIMP-high tumors. The protective effect 
associated with regular NSAIDs use largely disappeared among heavy smokers 
(Slattery et al., 2007). Using a cross-sectional design, Zhang and colleagues reported a 
trend of higher levels of LINE-1 methylation with higher levels of physical activity 
(Zhang et al., 2011a).  
 
Body mass index Several studies investigating LINE-1 and Alu methylation levels were 
not correlated with BMI; in contrast, in a study of women of child bearing age, 
Piyathilake et al. (2011) found that higher BMI was associated with lower LINE-1 
methylation. Obese individuals were at 2-fold increased risk of CIMP-low colon cancer, 
but obesity does not influence CIMP-high tumors (Slattery et al., 2007).  
 
Energy restriction during adolescence and early adulthood is associated with the CIMP 
phenotype in CRC, suggesting that exposure to a transient environmental condition 
during this period of life may result in persistent epigenetic changes that later influence 
CRC development. Individuals exposed to a period of severe short-term energy 
restriction had a decreased risk of developing a CIMP tumor later in life respect to 
individuals who were not exposed. During the years with a rapid growth and hormonal 
change, insulin-like growth factor-1 (IGF-1) can be four-times the normal adult serum 
concentration. IGF-1 inhibits apoptosis and stimulates proliferation of colonic epithelial 
cells in vitro. High levels of IGF-1 have been associated with a significant increase in 
colon cancer risk (Olivo-Marston et al., 2009). It could be possible that energy 
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restriction, during puberty, may permanently influence the growth hormone-IGF axis, 
subsequently influencing methylation patterns later in life (Hughes et al., 2009).  
 
Some studies in humans evaluated the association between DNA methylation and other 
environmental factors such as benzene, persistent organic pollutants, and air 
contaminants.  Benzene: Low-dose benzene exposure was associated with decreased 
methylation of LINE-1 and Alu sequences, and with hypermethylation of p15 and 
hypomethylation of MAGE-1. In patients with benzene poisoning, the average 
methylation level of p16
Ink4A
 was higher respect to controls.  
 
Persistent organic pollutants: Some studies investigate the correlation between plasma 
persistent organic pollutant (POP) concentrations and WBC global DNA methylation 
and found a significant inverse linear relationship for DDT, DDE, β-
hexachlorocyclohexane, oxychlordane, α-chlordane, mirex, several PCBs and the sum 
of all persistent organic pollutants with Alu methylation. A study in Korea found that 
some pesticides were inversely and significantly associated with Alu methylation; 
however there are still contrasting results (Rusiecki et al., 2008). 
 
Air pollution. The effects of particulate matter (PM) exposure on Alu, LINE-1 and 
gene-specific methylation was examined in steel plant workers. Long-term exposure to 
PM10 was negatively associated with methylation in both Alu and LINE-1. Exposure to 
black carbon (BC), a marker of traffic particles, was also associated with decreased 
DNA methylation in LINE-1. NOS2 promoter methylation was significantly lower in 
post-exposure blood samples compared to baseline (Madrigano et al., 2011; Tarantini et 
al., 2009).  
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Folate metabolism, also known as one-carbon metabolism, is fundamental for the 
synthesis of DNA and RNA precursors or for the conversion of homocysteine (Hcy) to 
methionine, which is then used to form the main DNA methylating agent S-
adenosylmethionine. Folic acid supplementation might protect the developing 
colorectum because of its critical role in maintaining DNA stability. In vitro animal and 
human studies show that folate deficiency induces epigenetic changes leading to global 
DNA hypomethylation, protooncogene activation and CIN; moreover, folate provide 
the nucleotide precursors for DNA synthesis and replication, ensuring DNA fidelity, 
maintenance of DNA integrity, and optimal DNA repair. In the normal colorectum, 
folate deficiency appears to enhance, whereas folic acid supplementation suppresses, 
the development of CRC. In contrast, once aberrant crypt foci are established, folate 
deficiency inhibits the progression and induces regression of these established pre-
neoplastic foci (Kim, 2007; Kim, 2008). A deficiency of methyl groups in the diet 
might lead to hypomethylation of DNA in several tissues, including blood. Global and 
p53 gene DNA was hypomethylated in human colon adenoma cells grown in folate-
depleted medium but was restored by folic acid repletion (Wasson et al., 2006). 
Lymphocyte DNA is hypomethylated in women made experimentally folate deficient 
over several weeks (Jacob et al., 1998; Rampersaud et al., 2000) and low-dietary folate 
intake (<200 mg/d) correlates with hypomethylation of LINE-1 in human colon tumors 
(Schernhammer et al., 2010). Several studies, using rat models of CRC, showed that the 
maternal folic acid supplementation significantly reduced the CRC risk by 64% in the 
offspring, whereas post weaning folic acid supplementation had no effect; moreover, 
tumor multiplicity were significantly higher in the pups from the dams fed the control 
diet and with post weaning folic acid supplementation than those without post weaning 
supplementation; it has been hypothesized that the pups from the dams with control diet 
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have developed precancerous lesions in the colorectum respect to those from the folic 
acid-supplemented dams; then post weaning folic acid supplementation might have 
promoted the progression of these pre-neoplastic lesions (Lindzon et al., 2009; Sie et 
al., 2011). Studies carried out in United States and Chile suggest that increased intake 
of synthetic folic acid has increased colon cancer risk (Mason et al., 2007; Hirsch et al., 
2009). However, low dietary folate intake (<200 μg/day) was also associated with an 
increased frequency of hypomethylated long-interspersed nucleotide element (a marker 
of genome-wide DNA methylation) repeats in human colon tumors (Schernhammer et 
al., 2010). Folate deficiency significantly increased hepatic OGG-1 and MGMT repair 
activity. Probably the upregulation of these two proteins indicates the occurrence of 
DNA damage lending further support to the finding that increased DNA damage 
(including DNA strand breaks, uracil misincorporation and oxidised bases) is a 
consequence of folate deficiency. Low folate intake significantly increased 8-oxo-7,8-
dihydroguanine levels in DNA in lymphocytes from rats fed the folate deficient diet. 
Although there were highly significant changes in OGG-1 and MGMT expression in rat 
liver in response to folate depletion, no such effects were seen in colon, indicating that 
the ability of the liver to respond to folate deficiency is not shared by the colon. The 
colon cannot respond such as the liver to damage and would therefore be more 
susceptible to the genotoxic effects instigated by folate deficiency (Duthie et al., 2010). 
A key question is whether the findings from these animal studies can be extrapolated to 
humans. Little is known currently about the effect of folate status on DNA repair in 
humans. NER is impaired in lymphocytes from individuals with poor folate status (Wei 
et al., 2003). Conversely, supplementing healthy volunteers of adequate folate status 
with folic acid (1.2mg/day for 12 weeks) does not alter BER-mediated excision of 8-
oxo-7,8-dihydroguanine from lymphocytes (Basten et al., 2006). They have also shown 
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that MGMT activity in normal human colorectal mucosa is inversely associated with 
vegetable consumption and that high dietary folate intake is related to low DNA 
alkylation damage. If this inability of colon tissue to upregulate DNA repair processes 
occurs in humans, it may constitute one of the mechanism through which folate 
deficiency increases the potential for malignant transformation (Duthie et al., 2010). 
Low levels of folate in the diet or in blood were associated with higher CRC risk; 
inversely high intake of folate has been associated with reduced CRC risk (Du et al., 
2010). It also observed that high plasma folate levels may be associated with increased 
CRC risk (Van Guelpen et al., 2006). In a study a small trend for higher levels of serum 
folate was observed in the group of patients with methylated tumors, compared to those 
with unmethylated tumors; moreover it was observed a trend for association between 
serum folate/vitamin B12 levels and gene promoter methylation: higher 
serumfolate/vitamin B12 levels were strongly associated with promoter methylation of 
p16
Ink4A
 and had an association trend with promoter methylation of MLH1 and MLH2 
genes (Mokarram et al., 2009). RBC folate levels were found positively associated with 
ERα and SFRP1 methylation levels. These data have important implications regarding 
the safety of supplementary folate administration in healthy adults, given the hypothesis 
that methylation in normal mucosa may be a predisposing phenomenon for colorectal 
neoplasia (Wallace et al., 2010). Alterations in folate metabolizing genes or deficiency 
of folate can result in elevated homocysteine levels. Folate deficiency is significantly 
more associated with oncogenesis when combined with hyper-omocysteinemia 
(increased risk of 17 times of carcinogenic lesions); moreover, inflammatory bowel 
disease patients with folate deficiency and hyperhomocysteinemia might be associated 
with increased risk colorectal cancer (Phelip et al., 2008). The effect of intervention 
with folic acid on DNA methylation is thereby conflicting and highly dependent on 
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initial folate status, level and duration of supplementation, tissues examined, stage of 
malignant transformation, and polymorphisms in folate metabolizing genes (Sie et al., 
2011). 
 
Global DNA hypomethylation is the first epigenetic alteration that was recognized in 
CRC, occurring gradually, age dependently (Suzuki et al., 2006). Growing evidence 
supports that WBC global DNA methylation, particularly in blood, changes with age. 
Studies have correlated age with two of the repetitive elements, LINE-1 and Alu. 
Although one study correlated positively lower levels of LINE-1 methylation with 
increasing age, most of the studies did not find an age- dependent effect on blood LINE-
1 methylation. In contrast, all of the studies investigating age and Alu methylation 
supported a lower level of DNA methylation of this repetitive element DNA with 
increasing age. On the other hand hypermethylation of tumor suppressor genes could be 
positively correlate with age (An et al., 2010). 
Many studies have found that global DNA methylation was higher in males than in 
females. Of the repetitive elements, LINE-1 was associated with lower levels in females 
compared to males in most but not all studies. On the other hand there has been no 
consistent pattern associated with Alu methylation. A gender-dependent difference in 
gene-specific methylation in blood was also reported for CALCA, MGMT, MTHFR, 
MAOA, DRD4, SERT and F8 genes (See review Terry et al., 2011).  
 
 
1.7 Genetic factors affecting DNA methylation in colorectal cancer  
 
Folate is a fundamental nutrient mainly required for either DNA synthesis or 
methylation processes. Particularly, it is required for the synthesis of S-
adenosylmethionine (SAM) the major intracellular methyl donor. The availability of 
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SAM is directly influenced by the diet. SAM is formed from methyl groups derived 
from choline, methionine, or methyltetrahydrofolate (MTHF). Because of their 
involvement in DNA methylation, single nucleotide polymorphisms (SNPs) in genes 
involved in folate metabolism could be associated with either aberrant gene methylation 
or CIMP. Indeed, several polymorphisms of genes involved in folate metabolism, 
including methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C, 
methionine synthase (MTR) A2756G andmethionine synthase reductase (MTRR) A66G; 
thymidylate synthase (TYMS) 28 bp repeats, DNA methyltransferase (DNMT3B) -
149C>T, and the transcobalamin II (TCNII) 776G variant, often in combination with 
folate intake, have been associated with CRC risk, CIMP, MSI phenotypes, and aberrant 
methylation of CRC genes (Karpinski et al., 2010; De Vogel et al., 2009; Iacopetta et 
al., 2009; Yamaji et al., 2009; Curtin et al., 2007; Eaton et al., 2005; Kang et al., 2005; 
Keku et al., 2002; Levine et al., 2000; Slattery et al., 1999). 
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2. DNA methylation analysis techniques 
There are many techniques used to investigate DNA methylation, including methylation 
specific PCR (MSP), quantitative MSP and Methylation sensitive-High Resolution 
Melting (MS-HRM). MSP allows the determination of the methylation status of a gene 
by means of two specific sets of primer, the first specific for the methylated template 
and the latter for the unmethylated one. It is important to include several CpG sites 
towards the 3’end of the primers to have a specific binding and amplification of only 
methylated variants of the template (in concert with stringent PCR conditions). MSP 
assays are normally associated with high false-positive rates, events that could happen 
with the mismatches of the primer sequence with the template or with the incomplete 
bisulfate conversion. False priming events could be prevent by a minor number of  
cycles and or using a higher annealing temperature. In the traditional MSP technique a 
second set of primers is designed for the amplification of unmethylated DNA. Gel 
electrophoresis is used to analyze the PCR products and to evaluate (in case in which 
both unmethylated DNA and methylated DNA are present in the test tube), by means of 
the band strengths, an approximation of the methylation status of the sample. A 
quantitative  MSP technique is the Methylight assay. Some methylation studies use one 
primer set (MIP, methylation independent primer) to obtain a PCR product from 
bisulfite modified template regardless of its methylation status. MS-HRM combines 
PCR amplification using methylation independent primers with subsequent HRM 
analyses of the PCR products; the PCR products generated from a methylated template 
has a higher GC content and therefore higher melting temperature respect to PCR 
products obtained from an unmethylated template. This technique allows for estimation 
of the methylation level by comparing the melting profiles of unknown PCR products to 
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the melting profiles of PCR products derived from DNA standards with a known 
unmethylated to methylated template ratio. 
Cloning and sequencing provide information about CpG methylation on the same 
molecule instead Pyrosequencing provides an average of the many molecules analyzed 
simultaneously (Tost and Gut, 2007). Pyrosequencing is a sequence by synthesis 
method that is the only method analyzing methylation levels at each CpG sites 
separately; nevertheless, this technique is much expensive. During Pyrosequencing PPi 
molecules are released, after incorporation of nucleotides, and are quantitatively 
converted into a bioluminometric signal; particularly the PPi is converted into ATP by 
the ATP sulfurylase, using adenosine 5’ phosphosulfate as substrate. The energy  
obtained is necessary for the luciferase to oxidize D-luciferin. The nucleotide dATP acts 
as a substrate for luciferase, thus it is important to use the modified a-S-dATP as the 
nucleotide for primer extension. Unincorporated nucleotides are eliminated before the 
new nucleotide is inserted by the apyrase. If the second nucleotide added is not 
complementary to the template sequence, no PPi is released and the nucleotide is 
degraded. In the template sequence there is a potential methylation variable position 
(CpG site) where C (methylated cytosine before bisulfite treatment) or T (unmethylated 
cytosine before bisulfite treatment) can be incorporated and the respective ratio yields 
the methylation degree at this CpG position. If 50% of the molecules incorporate a C, 
we can seen a peak of half of the intensity compared to first A peak corresponding to a 
single nonpolymorphic nucleotide incorporation. The other half of the molecules is 
complementary to the T added after the dispensation of the C nucleotide and the 
degradation of any unincorporated Cs. If the other two nucleotides in the template 
sequence are identical, these result in a peak of twice the height compared with the first 
A peak (Tost and Gut, 2007). 
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Many techniques used to investigate DNA methylation, particularly those that are based 
on methylation specific PCR (MSP), assume that DNA methylation is homogeneous, 
making data obtained from heterogeneously methylated regions difficult to interpret; 
amplicons derived from fully methylated sequences will not form heteroduplex with 
amplicons derived from fully unmethylated sequences. When methylation is 
heterogeneous, heteroduplex form because of the presence of molecules that differ only 
by a few bases. The MS-HRM is capable of analyzing homogeneous methylation in a 
semiquantitative manner. Heterogeneous methylation is not quantifiable, but is 
recognizable by its characteristic melting profiles. Samples that show an earlier melt 
compared to unmethylated control are heteroduplex that have low levels of DNA 
methylation. Other samples that finish melting shortly after the unmethylated control 
could have low or moderate levels of DNA methylation that is also heterogeneous. The 
lowest mean value of methylation of a sample analyzed with PYRO can be explained 
either by the presence of very few heavily methylated epialleles in a large background 
of unmethylated alleles or by the presence of epialleles which have only a smaller 
number of GpG dinucleotides methylated across the entire amplicon. MS-HRM and 
pyroseqencing provide to complementary information for the assessment of 
heterogeneous methylation (Candiloro et al, 2011). 
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Materials and Methods  
 
 
1. Study population  
 
Surgically resected tumor tissues and adjacent normal tissues (at 20 cm of distance) 
were collected from 59 patients (mean age= 69.7±11.7); staging was assessed after 
pathological examination of specimens based on TNM classification (Table 3). Not all 
the healthy tissue are available. For the other samples at the moment there is no 
available histological material. Blood samples have been also collected from the 
patients to obtain plasma folate, homocysteine and vitamin B12 values and to analyze 
polymorphisms in folate metabolism genes. The study was approved by the ethical 
committee and is sponsored by ITT. The individuals gave their written informed 
consent. The samples were obtained from the Department of Surgery of University of 
Pisa (Prof. P. Miccoli). The study includes also the recruitment of 9 patients (mean age= 
72.3± 8.8) obtained from the Medical School, Institute for Ageing and Health, 
University of Newcastle, UK (Prof. J. Mathers) (Table 3). 
 
Table 3: Demographics characteristics of the study population  
Patients Gender Age Duke's stage 
(TNM stage) 
Tumor size Cancer 
Location * 
P2 F 61 C (Stage III) T3 C 
P3 M 42 B (Stage II) T3 C 
P4 M 79 n.a n.a n.a 
P5 M 73 n.a. T1 n.a. 
P6 F 86 B (Stage II) T2 C 
P7 F 78 n.a n.a n.a 
P8 M 63 A (Stage I) T1 C 
P9 F 62 B (Stage II) T3 C 
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P10 M 68 C (Stage III) T3 C 
P11 M 76 B (Stage II) T3 C 
P12 F 80 C (Stage III) T3 C 
P13 M 71 C (Stage III) T3 SR 
P14 M 58 C (Stage III) T3 C 
P15 F 70 A(Stage 0) Tis n.a. 
P16
INK4A
 F 71 A (Stage I) T2 C 
P17 F 47 C (Stage III) T3 S 
P18 M 77 A (Stage I) T2 C 
P19 M 72 C(Stage III) T3 SR 
P20 F 74 D (Stage IV) T3 C 
P21 M 85 B (Stage II) T3 C 
P22 F 79 D (Stage IV) T3 SR 
P23 M 48 B (Stage II) T3 SR 
P24 M 87 B (Stage II) T3 C 
P25 M 81 D (Stage IV) T3 C 
p26 M 58 C (Stage III) T3 SR 
P27 M 77 B (Stage II) T3 S 
P28 F 64 A (Stage I) T2 SR 
P29 F 56 C (Stage III) T3 R 
P30 F 84 Tubulo-villous 
adenoma 
Tubulo-villous 
adenoma 
C 
P31 F 82 Polyp Polyp C 
P32 F 82 B (Stage II) T3 C 
P33 M 78 n.a. n.a. n.a. 
P34 M 73 C (Stage III) T2 n.a. 
P35 M 76 B (Stage II) T3 C 
P36 F 82 B (Stage II) T3 C 
P37 M 64 n.a. n.a. S 
P38 M 50 B (Stage II) T3 SR 
P39 M 60 B (Stage II) T3 C 
P40 M 68 B (Stage II) T3 C 
P41 F 62 C (Stage III) T3 C 
P42 M 81 A (Stage I) T2 S 
P43 F 85 D (Stage IV) T4 C 
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P44 M 48 A (Stage I) T2 C 
P45 F 87 B (Stage II) T3 C 
P46 M 82 C (Stage III) T3 SR 
P47 M 63 D (Stage IV) T3 C 
P48 M 50 n.a. n.a. n.a. 
P49 F 50 B (Stage II) T3 SR 
P50 M 57 C (Stage III) T3 S 
P51 M 65 A (Stage I) T2 C 
P52 F 85 D (Stage IV) T4 C 
P53 M 70 A (Stage I) T2 SR 
P54 F 52 D (Stage IV) T4 C 
P55 M 64 B (Stage II) T3 RS 
P56 F 70 C (Stage III) T3 C 
P57 M 82 B (Stage II) T3 C 
P58 M 71 D (Stage IV) T3 C 
P59 F 71 C (Stage III) T3 C 
P60 F 52 C (Stage III) T3 C 
42T (Nc) M 79 B (Stage II) T2 R 
45T (Nc) M 61 C (Stage III) T3 R 
54T (Nc) M 61 C (Stage III) T3 R 
55T (Nc) M 64 B (Stage II) T2 SR 
57T (Nc) F 75 C (Stage III) T3 C 
63T (Nc) M 77 C (Stage III) T3 C 
64T (Nc) M 70 B (Stage II) T2 S 
65T (Nc) M 78 B (Stage II) T2 S 
48 T (Nc) 
 
F 86 B (Stage II) T2 C 
(* C: Colon; R: Rectum, S: Sigma SR: Sigma-Rectum). 
 
2. Isolation of human epithelial cells 
Where possible, human epithelial cells were isolated from colon-rectal cancer and 
healthy tissues through immunomagnetic method with microbeads coated with the 
antibody CD326+, specific for epithelial cells. Briefly the method consist of enzymatic 
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dissociation of tissue fragments  with collagenase-H, filtration with sterile filters and 
epithelial cells purification by immunomagnetic method (Miltenyi Biotec) (Experiments 
performed in the  Prof. Consolini laboratory).  
 
3. Extraction of genomic DNA  
Genomic DNA was extracted using QIAmp DNA blood Mini Kit (Qiagen, Milan, Italy) 
according to the manufacturer’s instruction.  
 
4. Genotyping 
The genotyping for MTHFR C677T, MTHFR A1298C, TYMS 28 bp repeats, TYMS 6 bp 
deletiom, MTR A2756G, MTRR A66G, DNMT 3B –C149T, DNMT 3B-G579T were 
performed according to PCR-RFLP methods described in Coppede et al., 2006 and 
Coppedè et al., 2012. All PCR reactions were done separately in a 25 ul reaction 
volume containing 1.25 units of Taq DNA polymerase (Invitrogen), 1.5 mM of MgCl2, 
1x PCR buffer (Invitrogen), 10 pmol of each primers and 30 ng of genomic DNA. All 
PCR reactions were set with an initial denaturation of 5 min at 95° C and subsequently 
denatured for 30 s at 95°C, with annealing for 30 s at the appropriate temperature (see 
table 4) and extension for 30 s at 72°C. Thirty five cycles were used to amplify the PCR 
products to the expected sizes; the amplicons were subsequently digested using 
appropriate restriction enzymes (Fermentas). Figure 7 shows an image regarding the 
electrophoresis gel done to discriminate the different genotypes of MTHFR C677T (the 
images relative to the other polymorphisms are not shown). 
 
 
 
Table 4: Primer sequences and annealing temperature used in polymorphisms analyses. 
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Table 4: Primer sequences and annealing temperature used in polymorphisms analyses. 
 
 
 
 
 
Figure 7: MTHFR C677T genotypes: Digestion produced 175 e 23-bp in the presence of 677T allele, a 198bp 
fragment in the presence of 677C allele. 
 
 
5. Methylation analysis 
The extracted DNA was quantified using a Nano Drop ND 2000c spectrophotometer 
(NanoDrop Thermo scientific, Wilmington, DE). 250 ng of DNA from each subject 
have been treated with sodium bisulfite using the “EpiTect® Bisulfite Kit” (Qiagen, 
Milan, Italy) according to the manufacturer’s protocol. Sodium bisulfite treatment 
CC CT CTCT CTTT TT
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converts all unmethylated cytosines into uracil, whilst methylated cytosines are left 
unchanged. After sodium bisulfite treatment MS-HRM analysis was performed as 
described as follows. In this work we compare the analytical performances and the 
predictive values of two technique (MS-HRM and Pyrosequencing). Protocols for 
Methylation Sensitive High Resolution Melting (MS-HRM) have been developed in our 
laboratory (Prof. Lucia Migliore)  by modifying literature methods (Wojdacz and 
Dobrovic, 2007; Huang et al, 2010). The Pyrosequencing was performed in the 
laboratory of Prof. John Mathers (Newcastle University).  
Standard curves with known methylation ratios were included in each assay and were 
used to deduce the methylation ratio of each tumor and normal sample. The HRM 
standard melting curves were derived from six samples with the following ratios of 
methylation: 0%, 12,5%, 25%, 50%, 75%, 100%. Fully methylated and unmethylated 
bisulfite converted DNA (Qiagen) were mixed to obtain the different percentages of 
methylation.  
 
5.1 MS-HRM protocols  
MS-HRM for APC: PCR amplification and HRM were performed on CFX 96™ Real-
Time (BioRad). The sequences of the primers for APC are as follows: forward- 
CGGGGTTTTGTGTTTTATTG and reverse - TCCAACGAATTACACAACTAC. PCR was 
performed in a 25 ul volume containing: 12,5 ul of master mix (Qiagen) 10 pmol of 
each primer and 50 ng bisulfate treated DNA template. Each reaction was performed in 
duplicate. The cycling conditions were: 1 cycle of 95°C for 12 min, 60 cycles of 95°C 
for 30 s, 56 °C for 45 s, and 72°C for 45 s; followed by an HRM step of 95°C for 10 s 
and 50°C for 1 min, 65° C for 15 s, and continuous acquisition to 95°C at 1 acquisition 
per 0.2°C. The PCR product was of 71 bp (4 CpG sites analyzed). Figure 8 shows the 
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melting curves regarding the standards and one sample in duplicate (50-75% of 
methylation) 
 
Figure 8: melting curves of APC gene: the standards and a sample in duplicate (highlighted) 
 
MS-HRM for CDKN2A: PCR amplification and HRM were performed on CFX 96™ 
Real-Time (BioRad). The sequences of the primers for CDKN2A (p16
Ink4A
) are as 
follows: forward- CGGAGGAAGAAAGAGGAGGGGT and reverse 
CGCTACCTACTCTCCCCCTCT. PCR was performed in a 25 ul volume containing: 12,5 ul 
of master mix (Qiagen) 10 pmol of each primer and 50 ng bisulfate treated DNA 
template. Each reaction was performed in duplicate. The cycling conditions were: 1 
cycle of 95°C for 12 min, 60 cycles of 95°C for 30 s, 62°C for 45 s, and 72°C for 45 s; 
followed by an HRM step of 95°C for 10 s and 50°C for 1 min, 68° C for 15 s, and 
continuous acquisition to 90°C at 1 acquisition per 0.2°C. The PCR product was of 93 
bp (7 CpG sites analyzed). Figure 9 shows the melting curves regarding the standards 
and two samples in duplicate with 12.5-25% of methylation (red arrow)  and 0% of 
methylation (yellow arrow). 
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Figure 9: melting curves of CDKN2A gene: the standards and two samples in duplicate (highlighted) 
  
MS-HRM for MGMT: PCR amplification and HRM were performed on CFX 96™ 
Real-Time (BioRad). The sequences of the primers for MGMT are as follows: forward-
GCGTTTCGGATATGTTGGGATAAGT and reverse- AACGACCCAAACACTCACCAAA. PCR 
was performed in a 25 ul volume containing: 12,5 ul of master mix (Qiagen) 10 pmol of 
each primer and 50 ng bisulfate treated DNA template. Each reaction was performed in 
duplicate. The cycling conditions were: 1 cycle of 95°C for 12 min, 60 cycles of 95°C 
for  30 s, 58°C for 45 s, and 72°C for 30 s; followed by an HRM step of 95°C for 10 s 
and 50°C for 1 min, 68° C for 15 s, and continuous acquisition to 90°C at 1 acquisition 
per 0.2°C. The PCR product was of 110 bp (12 CpG sites analyzed). Figure 10 shows 
the melting curves regarding the standards and two samples in duplicate with 0-12.5% 
of methylation. 
 56 
 
 
Figure 10: melting curves of MGMT gene: the standards and two samples in duplicate (highlighted) 
 
MS-HRM for hMLH1: PCR amplification and HRM were performed on CFX 96™ 
Real-Time (BioRad). The sequences of the primers for hMLH1 are as follows: forward- 
AGTTTTTAAAAAC/TGAATTAATAGGAAGAG and reverse- 
ACTACCCGCTACCTAAAAAAATATAC. PCR was performed in a 25 ul volume 
containing: 12,5ul of master mix (Qiagen), 15 pmol of each primer and 50 ng bisulfate 
treated DNA template. Each reaction was performed in duplicate. The cycling 
conditions were: 1 cycle of 95°C for 12 min, 60 cycles of 95°C for 15 s, 56°C for 15s, 
and 72°C for 15s; followed by an HRM step of 95°C for 30 s and 50°C for 1 min, 65° C 
for 15 s, and continuous acquisition to 95°C at 1 acquisition per 0.2°C. The PCR 
product was of 81 bp (5 CpG sites analyzed). Figure 11 shows the melting curves 
regarding the standards and two samples in duplicate with 0 % of methylation. 
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Figure 11: melting curves of h MLH1 gene: the standards and a sample in duplicate (highlighted) 
 
MS-HRM for hMLH1: It is also performed a MS-HRM with primers used in 
Pyrosequencing (. PCR amplification and HRM were performed on CFX 96™ Real-
Time (BioRad). The sequences of the primers for hMLH1 are as follows: forward- 
GGTTATAAGAGTAGGGTTAA and reverse- ATACCAATCAAATTTCTC. PCR was 
performed in a 25 ul volume containing: 12,5ul of master mix (Qiagen), 15 pmol of 
each primer and 50 ng bisulfate treated DNA template. Each reaction was performed in 
duplicate. The cycling conditions were: 1 cycle of 95°C for 12 min, 60 cycles of 95°C 
for 30 s, 48°C for 15s, and 72°C for 30s; followed by an HRM step of 95°C for 10 s and 
50°C for 1 min, 68° C for 15 s, and continuous acquisition to 85°C at 1 acquisition per 
0.2°C. PCR product was of 307 bp (18 CpG sites analyzed). Figure 12 shows the 
melting curves regarding the standards and two samples in duplicate with 50-75% of 
methylation 
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Figure 12 melting curves of h MLH1 gene (with Pyrosequencing primer): the standards and a sample in duplicate 
(highlighted) 
 
MS-HRM for RASSF1A: PCR amplification and HRM  were performed by the CFX 
96™ Real-Time (BioRad).The sequences of the primers for hRASSF1A are as follows: 
forward- TCGGGTTTTATAGTTTTTGTATTTAGGTTTT and reverse- 
CCTCCCCCAAAATCCAAACTAA. PCR was performed in a 25 ul volume containing: 12,5 
ul of master mix (Qiagen) 10 pmol of each primer and 50 ng bisulfate treated DNA 
template. Each reaction was performed in duplicate. The cycling conditions were: 1 
cycle of 95°C for 12 min, 60 cycles of 95°C for 30 s, 60°C for 45 s, and 72°C for 45 s; 
followed by an HRM step of 95°C for 10 s and 50°C for 1 min, 65° C for 15 s, and 
continuous acquisition to 95°C at 1 acquisition per 0.2°C. The PCR product was of 87 
bp (7CpG sites analyzed). Figure 13 shows the melting curves regarding the standards 
and two samples in duplicate with 0% of methylation. 
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Figure 13: melting curves of RASSF1A gene: the standards and a sample in duplicate (highlighted) 
 
5.2 Pyrosequencing protocols 
Genomatix software (www.genomatix.de) Gene2Promoter allows to look for a 
promoter regions within sequenced genomes of various organisms. In parallel in 
Genomotix it is possible to see transcription factor binding sites.  
PSQ software was used to design the primers. Bisulfite modified (BM) 0% and 100% 
DNA should be used in a pre-PCR dilution series to produce 0, 25, 50, 75, 100% BM 
DNA. These dilutions should be used for subsequent Pyrosequencing PCR. Usually the 
standard conditions for the PyroPCR are: 12,5 of Taq Mastermix (Qiagen), 10pmol of 
each primers and 250 ng of BM DNA in a total volume of 25 µL. The PyroPCR 
temperature profile was the follow: 95°C for 15min, 94°C for 15 s, X°C for 30 s, 72°C 
for 30 s (Repeat steps 2, 3, 4 x50 times) and 72°C for 10 min. After PyroPCR, the DNA 
concentration varies due to the reaction condition, but it will usually fall in the region 
15-30 ng/µL. Figures 14 and 15 show the APC and CDKN2A Pyrosequencing validation 
with pre-PCR standard dilution. It is reported only the first CpG site of the analyzed 
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region. For the other two genes (MGMT and hMLH1) it was utilized the standardized 
protocol used in John Mathers laboratory. 
 
 
 
Figure 14: APC Pyrosequencing validation 
 
 
Figure 15: CDKN2A Pyrosequencing validation 
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Biotinylated PCR products are immobilised on streptavidin-coated beads. Parallel 
immobilisation of several samples can be performed in a sealable 96 well PCR plate. It 
is important: 1)Allow all solutions to reach room temperature before starting; 2) Turn 
on heat block to 80°C; 3) Shake bottle of streptavidin beads to obtain a homogenous 
solution. 
The Binding buffer solution is constituted by 2µl beads, 38µl binding buffer  and 30µl 
H20. The passages are: transfer 70µl of this solution into a PCR plate (shaking after 
every few wells to prevent beads settling). Thus add 10µl of PyroPCR product to 
binding buffer solution in PCR plate (NB: when the PCR product on gel shows very 
strong band, you could use only 5 µl). Subsequently: 
1. Seal plate and shake for 10mins. 
2. Whilst the plate is shaking prepare the Pyrosequencing plate by making the 
annealing solution.  Make a master mix with the following volumes per sample: 
11.5µl of annealing buffer and 0.5µl (5pmol/µl) of sequencing primer. Add 12µl 
of this to each corresponding well on a pyro plate. 
For the strand separation, fill four square plastic troughs with appropriate solutions up 
to the line of troughs: 
 probe block dH20 
2.Denaturing buffer (NaOH) 4.dH20 
1.Ethanol 3.Wash buffer 
PCR plate Pyro plate 
 
1. Switch on vacuum pump and prime the probes by sucking through dH20 for a 
few sec. 
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2. Remove plate from shaker and immediately apply vacuum sample prep tool 
(head).  Make sure all the sample has been taken up from the plate. 
3. Follow the pattern 1→2→3, so: 
4. Place vacuum tool in ethanol trough – once liquid flows through tool count 5 
sec and remove, leaf to dry a bit. Repeat this for the denaturing and then wash 
buffer. 
5. Turn off vacuum, place tool into Pyrosequencing plate to release the single 
stranded PCR product into the annealing solution – rock or shake for several 
sec 
6. Place the plate on to the pre-heated heat block (80°C) and leave for 2min. Clean 
the vacuum tool by sucking H20 through for a few seconds. 
7. Remove plate and leave to cool for a few minutes, allowing the primer to anneal 
to PCR product. 
8. The plate is now ready for the Pyrosequencing. 
Thus it is necessary filling the reagent cartridge and place it with label facing you in the  
Pyrosequencer. Each tip should be labeled with the reagent it is used for, i.e. regent tips 
labeled E or S for enzyme and substrate and nucleotide tips labeled A, C, G or T. The 
enzyme tip should be filled with the appropriate amount of enzyme for assay and placed 
in the top left. The substrate tip should be filled with the appropriate amount of 
substrate for assay and placed in the top right. Nucleotides tips should be filled with 
care – sometimes air bubbles form in bottom which can interfere with dispensation – to 
remove flick tip. In table 5 are shown the different conditions (primers and annealing 
temperature) regards to genes analyzed by Pyrosequencing. Figures 16, 17 and 18 
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represent the images relatives to the CpG sites of the three promoter gene regions 
analyzed by Pyrosequencing. 
 
         Table 5: Pyrosequencing conditions and analyzed sequences 
(* CpG island B) 
         
 
Genes Primer Pyrosequencing
Annealing
temperature
CpG sites/amplicon lenght
APC F-TATTAATTTTTTTGTTTGTTGGGGA 
R-AACTACACCAATACAACCACATATC
Sequencing primer:
GGGGTTTTGTGTTTTATTG
55 C C/TGGAGTGC/TGGGTC/TGGGA
AGC/TGGAGAGAGAAGTAGTT
GTGTAATTC/TGTTGGATGC/TG
GATTAGGGC/TGT
CDKN2A F-AGAGGATTTGAGGGATAG
R-AATTCCCCTACAAACTTC
Sequencing primer: 
GGGTTGGTTGGTTATTA
50 C GAGGGTGGGGC/TGGATC/TGC
/TGTGC/TGTTC/TGGC/TGGTTG
C/TGGAGAGGGGGAGAGTAGG
TAGC/TGGGC/TGGC/TG
hMLH1 F-GGTTATAAGAGTAGGGTTAA
R-ATACCAATCAAATTTCTC
Sequencing primer:
TGTTTTTATTGGTTGGATAT
45 C TTC/TGTATTTTTC/TGAGTTTTT
AAAAAC/TGAATTAATAGGAA
GAGC/TGGATAGC/TGATTTTTA
AC/TGC/TGTAAGC/TGTA
MGMT* F-AGTTTTTTTGGTGGATATA
R-TACCTTTTCCTATCACAA
Sequencing primer: 
TTTAGGAGGGGAGAGAT
47 C TC/TGC/TGTTTC/TGGGTTTAG
C/TGTAGTC/TGTTTC/TGAGTA
GGATC/TGGGATTTTTATTAAG
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Figure 16: hMLH1 Pyrosequencing- 8 CpG sites analyzed in the CpG Island of hMLH1 gene. The y axis represents 
the signal intensity, while the x axis shows the dispensation order. The azure color indicate the % of methylation at 
each CpG site. 
 
Figure 17: APC Pyrosequencing: 7 CpG sites analyzed in the CpG Island of the APC gene. The y axis represents the 
signal intensity, while the x axis shows the dispensation order. The azure color indicate the % of methylation at each 
CpG site. 
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Figure 18: CDKN2A Pyrosequencing: 10 CpG sites analyzed in the CpG Island of the CDKN2A gene. The y axis 
represents the signal intensity, while the x axis shows the dispensation order. The azure color indicate the % of 
methylation at each CpG site. 
 
 
Note 1: For hMLH1 methylation analysis it was used two different couples of primer for 
MS-HRM: one set of primer (in green) and another set of primer (blue) also used in 
Pyrosequencing. The azure primer is the sequencing primer for hMLH1; thus the 
sequence analyzed in Pyrosequencing was least then MS-HRM sequence. Figure 19 
shows the whole analyzed sequence.  
 
 
 
Figure 19: hMLH1 sequence analyzed with both Pyrosequencing and MS-HRM. 
GGTTATAAGAGTAGGGTTAAC/TGTTAGAAAGGTC/TGTAAGGGGAGAGGAGGAGTTTGAGAAGC/TGTTAAGTATTT
TTTTC/TGTTTTGC/TGTTAGATTATTTTAGTAGAGGTATATAAGTTC/TGGTTTC/TGGTATTTTTGTTTTTATTGG
TTGGATATTTC/TGTATTTTTC/TGAGTTTTTAAAAAC/TGAATTAATAGGAAGAGC/TGGATAGC/TGATTTTTAAC
/TGC/TGTAAGC/TGTATATTTTTTTAGGTAGC/TGGGTAGTAGTC/TGTTTTAGGGAGGGAC/TGAAGAGATTTAGT
AATTTATAGAGTTGAGAAATTTGATTGGTAT. 
 
Legend: PIMER USED FOR MS-HRM; PRIMERS FOR PYRO and MS-HRM; SEQUENCING PRIMER 
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Note2: For MGMT methylation analysis we studied two different CpG island (A and B) 
regards to Pyrosequencing and MS-HRM and thus data from the two techniques are not 
comparable. 
 
6. Statistical analysis 
A data interpolation was performed to compare MS-HRM and Pyrosequencing 
methods: a curve according to the method of Polynomial interpolation was obtained. 
For this purpose the MatLab program and its function interpolating “polyfit” was used. 
The result coincides with that obtainable with the method of Lagrange interpolation and 
allows, starting from a note fluorescence, to find the respective percentage of 
methylation instead of a range of interest. Thus Student’s t-test was used to compare 
MS-HRM and Pyrosequencing values. ANCOVA was used to compare CpG sites 
methylation in ephitelial cells (CD326+) respects to the whole tumor tissue, using 
sample ID as covariate. ANCOVA was also used to correlate the APC, CDKN2A, 
MGMT, hMLH1, RASSF1A promoter methylation (obtained by means of MS-HRM) 
with clinic pathological characteristics. Finally ANCOVA was used to correlate CpG sites 
methylation of the four genes (APC, CDKN2A MGMT and hMLH1), analyzed by 
Pyrosequencing, with the MTHFR C677T and DNMT3B C-149T polymorphisms, including 
age, cancer location, gender,  simple ID,  tumor size and stage  as covariates. Analyses were 
performed with the STATGRAPHICS 5.1 Plus software package for Windows. 
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Aim of the study 
This thesis is a part of an ongoing project entitled “Correlation among Genetic, 
Epigenetic and Environmental factors in Colorectal Carcinoma”; it aims to study the 
relationship among diet factors,, focusing on folate, homocysteine, and vitamin B12, 
and polymorphisms of one carbon metabolism pathway genes, as well as methylation 
levels of CRC critical genes (APC, CDKN2A, hMLH1, MGMT and RASSF1A). For the 
study  the recruitment of almost 200 CRC patients within three years is planned.  The 
study will end on  January 2013.  
This thesis is focused on a cohort of  CRC patients recruited until end of February 2012. 
Moreover, in the frame of a collaboration with  Prof. John Mathers (Institute for Ageing 
and Health, University of Newcastle, UK) a group of 9 CRC patients  recruited in UK 
was also included for some comparisons. 
The study comprises the following  items: 
1. Validation of  the MS-HRM protocol, used for the methylation analysis, by 
comparing it with widely employed technique: Pyrosequencing. 
2. Evaluation of the influence of an immunomagnetic method with microbeads 
coated with the antibody CD326+, specific for epithelial cells, to evaluate if 
cancer epithelial (CD326+) cells from the surgically resected CRC tissue could 
give more accurate results in DNA  methylation  levels detection with respect to 
the whole CRC tissue. 
3. Detection of methylation levels (performed by MS-HRM) in promoters of of 
APC, CDKN2A, hMLH1, MGMT and RASSF1A genes in CRC and healthy 
adjacent tissue specimens. 
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4. Analysis of the correlation among the methylation status of the chosen genes 
and the clinical-pathological features of the patients. 
5. Analysis of the correlation among MTHFR C677T, DNMT3B C-149T  
polymorphisms and the methylation levels of APC, CDKN2A, hMLH1 and 
MGMT gene promoters. 
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Results  
1. Comparison between tumor and healthy tissue in 
CRC patients  
 
The sensitivity of MS-HRM analysis was tested by using diluitions of fully methylated 
DNA into unmethylated DNA. The HRM standard melting curves were derived from 
six samples with the following ratios of methylated DNA: 0, 12.5, 25, 50, 75, 100% of 
methylation. The normalized melting profiles of the amplicon from the same template 
were consistent between replicates and between different runs. From each CRC patient 
either a sample of tumor tissue, either a sample of healthy tissue, located near the 
cancerous lesion (about 20 cm distance) was collected. Tables 6, 7, 8, 9, 10 show the 
methylation data obtained in CRC tissues and adjacent healthy colon tissues (not always 
available for all the patients) obtained by means of MS-HRM for each of the five 
screened genes (APC, CDKN2A, MGMT, hMLH1, RASSF1A). It is possible to see that 
for each of them, methylation is more frequent in CRC tissue samples. Only in case of 
APC gene a consistent increase of methylation in the range 0-12.5% was found also in 
adiacent healthy tissue.  
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Table 6: MS-HRM in APC gene: percent of methylation in CRC and healthy adjacent tissue  
 
 
 
Table  7: MS-HRM in CDKN2A gene: percent of methylation in CRC and  healthy adjacent tissue 
 
 
 
Table 8: MS-HRM in hMLH1 gene: percent of methylation in CRC and  healthy adjacent tissue 
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Table 9: MS-HRM in RASSF1A gene: percent of methylation in CRC and  healthy adjacent tissue 
 
 
 
 
 
 
Table 10: MS-HRM in MGMT gene: percent of methylation in CRC and  healthy adjacent tissue 
 
*CpG Island A 
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2. Correlation between methylation and clinical-
pathological features 
 
For each of the studied genes we also analysed correlation between promoter TNM 
stage methylation by ANCOVA analysis of regression analysis multifactorial analysis 
of variance, including age, gender, tumor, size, tumor location as covariates. Figures 20, 
21, 22, 23, 24 show the correlation between methylation of analyzed genes and staging 
of cancers, using the other variables as covariates. No statistical association was found 
in any case. Statistically significant associations were found instead between MGMT 
promoter methylation (Figure 24) and increasing age, and between hMLH1 promoter 
methylation and increasing age (Figure 25). 
 
 
                           Figure 20: Correlation between APC promoter methylation and TNM stage   
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                 Figure 21: Correlation between MGMT  promoter (CpG island A) methylation and TNM stage 
 
 
 
 
 
                               Figure 22: Correlation between hMLH1 promoter methylation and TNM stage 
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Figure 23: Correlation between CDKNN2A promoter methylation and TNM stage 
 
 
 
 
Figure 24: Correlation between  RASSF1A promoter methylation and TNM stage 
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Figure 25: Correlation between  MGMT  promoter methylation (HRM results) and age: r =0.28, P=0.03 
           
 
 
 
Figure 26: Correlation between  hMLH1  promoter methylation (HRM results) and age: r =0.35 , P=0.007 
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3. Comparison between MS-HRM and 
Pyrosequencing techniques  
 
Experiments were performed to compare two different techniques (MS_HRM and 
Pyrosequencing) used to investigate DNA methylation levels. Figures 27, 28, 29, 30, 
31, 32 show the methylation profiles obtained for each patient with the two methods 
(analysis of three genes: hMLH1, APC and CDKN2A). In each case we obtained 
specular profiles of the methylation and no statistically significant difference in mean 
values, indicating that the two techniques are comparable. 
           Figure 27: Specular profile of APC methylation (%) obtained for each subject with the two techniques. 
 
 
      Figure 28: Comparison of mean values of APC methylation (%) using the two techniques. 
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            Figure 29: Specular profile of CDKN2A methylation (%) obtained for each subject with the two techniques. 
 
 
 
 
 
 
 
        Figure 30: Comparison of mean values of CDKN2A methylation using the two techniques 
 
 
 
 
 
 
 
Diagramma a scatola e baffi
0 20 40 60 80
MS_HRM
PYRO
% of methylation in CDKN2A promoter
D
if
fe
re
n
t
te
ch
n
iq
u
es
P value = 0.9; Student’s t-test
 78 
 
 
            Figure 31: Specular profile of  hMLH1  methylation gene obtained for each subject with the two techniques. 
 
 
 
 
 
 
 
           Figure 32: Comparison of mean values of  hMLH1 methylation using the two techniques 
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4. Tumor cells separation  
Human epithelial cells were isolated from colorectal cancer and healthy tissues through 
immunomagnetic method with microbeads coated with the antibody CD326+, specific 
for epithelial cells. We expected CD326+ cells had a greater % of methylation respect 
to tissue without separation (CD326+ and CD326-). Data obtained with Pyrosequencing  
were thus analysed for 9 samples. There was no statistically significant difference 
between the epithelial cells and the tissue without separation in the promoter 
methylation levels of APC, CDKN2A, MGMT and hMLH1 genes (Table 11), although 
few patients showed singularly a statistically significant difference between the two 
groups regarding the degree of methylation of these genes (data not reported). The table 
clearly shows that, on average, there was no significant difference in the levels of 
methylation of the selected genes between the two experimental conditions. 
 
 
 
Table 11: Comparison of methylation levels (detected by Pyrosequencing)  between whole tissue (without separation) 
and separated epithelial cells (CD326+ ) for four genes in 9 CRC patients. 
*p-value obtained by means ANOVA 
 
 
 
 
 
Genes 
CD236+ cells 
(mean of methylation) 
Cells without 
separation (mean of 
methylation) 
p-value
* 
APC 19.61 17.02 
0.1862 
 
CDKN2A 14.75 12.91 
0.469 
 
hMLH1 17.67 16.7 
0.82 
 
MGMT 72.68 68.17 
0.09 
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5. Polymorphisms in folate metabolism genes and 
methylation 
 
The CRC patients were genotyped for eight polymorphisms in one-carbon metabolism 
genes (MTHFR C677T, MTHFR A1298C, MTR A2756G, MTRR A66G, TYMS 28 bp 
repeats, TYMS 6 bp del, DNMT3B C-149T, DNMT3B G-579T). The distribution of the 
genotypes is provided in Table 12. In a subgroup (30 subjects) of our population, using 
data obtained by means of Pyrosequencing, we tested a possible correlation between 
both MTHFR C677T, DNMT3B C-149T and CpG sites methylation of APC, CDKN2A, 
hMLH1 and MGMT promoter genes (Figures 33, 34, 35, 36, 37, 38, 39, 40). There is a 
statistically significant correlation (adjusted for age, gender, location, simple ID, size 
and stage) between the MTHFR genotypes and APC and hMLH1 promoter methylation 
(P value = 0.0000 and P value = 0.003 respectively) (Figures 33, 35). For the other two 
genes there is not association with MTHFR C677T polymorphism (Figures 34, 36). 
Moreover there is a statistically significant association (adjusted for age, gender, 
location, sample ID, size and stage) between the DNMT3B genotypes and the APC, 
CDKN2A, hMLH1 and MGMT promoter methylation (P value = 0.045, P value = 
0.0000,  P value = 0.006, P value = 0.0002, respectively) (Figures 37, 38, 39, 40).  
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Table 12: Genotypes relative to polymorphisms in one-carbon metabolism genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polymorphisms Genotype frequencies 
MTHFR C677T CC: (37.1%) CT: (46.8%) TT: (16.1%) 
MTHFR A1298C AA: (54.6%) AC: (31.8%) CC: (13.6%) 
MTR A2756G AA: (78.1%) AG: (21.9%) GG: (0%) 
MTRR A66G AA: (37.5%) AG: (37.5%) GG: (25%) 
TYMS 28 bp 
repeats 
3R3R: (35.5%) 2R3R: (54.8%) 2R2R: (9.7%) 
TYMS 6 bp del 6+6+:  (38%) 6+6-:  (51.7%) 6-6-: (10.3%) 
DNMT3B C-149T CC: (36.2%) CT: (44.8%) TT: (19%) 
DNMT3B G-579T GG: (46.5%) GT: (35.7%) TT: (17.8%) 
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Figure 33:  Correlation between APC methylation and MTHFR C677T polymorphism, adjusted for age,  gender, 
location, sample ID, size and stage (P-value = 0.0000). 
 
Figure  34: Correlation between CDKN2A methylation and MTHFR C677T polymorphism, adjusted for  age,  gender, 
location, sample ID, size and stage (P-value = 0.5). 
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Figure 35: Correlation between hMLH1 methylation and MTHFR C677T polymorphism, adjusted for  age, gender,     
location, sample ID, size and stage (P-value = 0.003). 
 
 
 
Figure 36: Correlation between MGMT (CpG island B) methylation and MTHFR C677T polymorphism, adjusted for  
age,  gender, location, sample ID, size and stage (P-value = 0.24). 
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Figure 37: Correlation between APC methylation and DNMT3B C-149T polymorphism, adjusted for  age,  gender, 
location, sample ID, size and stage (P-value = 0.045). 
 
Figure 38: Correlation between CDKN2A methylation and DNMT3B C-149T polymorphism, adjusted for age, 
gender, location, sample ID, size and stage (P-value = 0.0000). 
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Figure 39: Correlation between hMLH1 methylation and DNMT3B C-149T polymorphism, adjusted for  age, gender, 
location, sample ID, size and stage (P-value = 0.006). 
 
Figure 40: Correlation between MGMT  methylation and DNMT3B C-149T polymorphism, adjusted for  age,  gender, 
location, sample ID, size and stage (P-value = 0.0002). 
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6. Folate, homocysteine and vitamin B12 values 
in CRC patients 
 
From blood samples plasma folate, homocysteine and vitamin B12 have been measured. 
For some patients these biomarkers were not available, due to technical reasons. 
Interestingly, several CRC patients have high plasma Hcy levels (above the normal 
range that is 4.3-11.1 μmol/l) (Table 13). 
 
Table 13: Folate, homocysteine and vitamin B12 values in CRC patients with  the demographic characteristics of the 
subgroup.  
 Age Gender Stage (TNM) Tumor 
size 
Hcy  
(μmol/l) 
Folati 
(ng/ml) 
Vit B12 
(pg/ml) 
P2 58 F C (Stage III) n.a 8,08 11,3 631 
 
P3 42 M B (Stage II) T3 4,04 5,8 455 
 
P4 79 M n.a n.a 17,67 7,3 523 
 
P5 73 M n.a. n.a. 15,29 5,6 337 
 
P6 86 F B (Stage II) T2 21,39 7,8 601 
 
P7 78 F n.a n.a 11,86 8,2 612 
 
P10 68 M C (Stage III) T3 7,48 n.a. n.a. 
 
P12 80 F C (Stage III) T3 6,54 n.a. n.a. 
 
P13 71 M C (Stage III) T3 20,44 6,1 203 
 
P14 58 M C (Stage III) T3 10,56 8,1 441 
 
P15 70 F A(Stage 0) Tis n.a. n.a. 403 
 
P16INK4A 71 F A (Stage I) T2 7,2 9,1 364 
 
P17 47 F C (Stage III) T3 6,15 14 331 
 
P18 77 M A (Stage I) T2 18,04 3,8 835 
 
P23 48 M B (Stage II) T3 9,56 4,7 543 
 
P27 77 M B (Stage II) T3 14,2 6,01 394 
 
P28 64 F A (Stage I) T2 5,53 10,7 914 
 
P41 62 F C (Stage III) T3 8,57 13,1 142 
 
P45 87 F B (Stage II) T3 n.a. 4,5 410 
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P47 63 M D (Stage IV) T3 10,65 5 620 
 
P49 50 F B (Stage II) T3 8,24 2,8 365 
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Discussion 
The transformation of normal colon epithelial cells to adenomas, and then to cancer, is 
believed to be an evolutionary process in which neoplastic cells acquire heritable 
genetic and epigenetic alterations that drive the cancerogenesis (Migliore et al., 2011). 
Gene promoter hypermethylation is now recognized to have an important role in cancer 
development through silencing gene transcription. It is also known that the genetic and 
epigenetic alterations cooperate to promote tumor formation; human cancers generally 
show global DNA hypomethylation accomplished by region-speciﬁc hypermethylation. 
Alterations of DNA methylation may result in chromosomal instability as a result of 
changes in chromatin structure. DNA hypermethylation of CpG sites silences various 
tumor-related genes. Numerous studies using candidate gene approaches and genome-
wide screening techniques demonstrated that methylation-induced silencing of 
biologically relevant genes in colorectal cancer is common and inﬂuences tumor 
behavior (Hinoue et al., 2012).  
In the present thesis the methylation profiles of five CRC-related genes, namely APC, 
MGMT, RASSF1A, hMLH1 and CDKN2A (p16
Ink4A
) by means of MS-HRM were 
analyzed. Much effort was put on the validation of methodological approaches 
employed. First of all we set up MS-HRM protocol by comparing literature 
methodological indications focusing in particular on primer design. Some methylation 
studies use one primer set (MIP, methylation independent primer) to obtain a PCR 
product from bisulfite modified template regardless of its methylation status; however, 
proportional amplification of methylated and unmethylated alleles is difficult to obtain, 
due to PCR bias favoring amplification of the unmethylated sequence (poor in CpG). 
Wodjacz et al (2009, 2008) proposed a method to avoid this preferential amplification; 
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they suggested the inclusion of CpG sites into the primer sequence in fact the primers 
with limited number of CpG sites are able to reverse PCR bias and detect methylated 
templates with significantly higher sensitivity respect to CpG free primers. MS-HRM 
combines PCR amplification using methylation independent primers with subsequent 
HRM analyses of the PCR products; the PCR products generated from a methylated 
template have a higher GC content and therefore higher melting temperature respect to 
PCR products obtained from an unmethylated template. The fragment amplified during 
MS-HRM should be of a particular size: a short product will give high sensitivity but 
limited resolution between different levels of methylation because of the smaller 
differences in melting profiles between methylated and unmethylated products 
(Wodjacz et al, 2007). MS-HRM is an in tube method; thus the analysis takes place 
without the PCR product leaving the tube where it was amplified. This is important for 
the rapidity that it affords and because it could allow to avoid contamination. Then it 
was investigated if any significant difference was detectable when evaluating the 
methylation profile of the selected genes with MS-HRM, with respect to the 
methylation profile achievable by means of Pyrosequencing. Results obtained by means 
of MS-HRM matches those obtained with Pyrosequencing in terms of global DNA 
methylation of the studied amplicons, assuming that the same CpG sites are analysed 
within the CpG island. However we can compare the data of these two techniques only 
using the same set of primers. In fact, as already discussed, the primer design is a 
critical point for gene-specific methylation studies. Results from MS-HRM and 
Pyrosequencing have shown to be quantitatively comparable (see Figure 27, 28, 29, 30, 
31, 32); the first technique is however a close-tube method, important condition to 
avoid possible contamination; moreover it is less expensive respect to Pyrosequencing; 
on the other hand this last method can give accurate information on the methylation 
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level regarding all the CpG sites collocated in the CpG island analyzed. MS-HRM 
technique results sensitive in particular when the samples contain a mixture of fully 
methylated and unmethyated templates, giving melting profiles comparable to standard 
melting curves; while in case of heterogeneous methylation the technique shows 
complex melting profiles, difficult to interpret. Quantification of heterogeneous 
methylation remains indeed difficult to detect; however these two techniques provide 
complementary information for the assessment of heterogeneous methylation because 
of the quantitative information.  
Then, we questioned whether or not a selection of cancer epithelial cells (CD326+) cells 
from the surgically resection CRC tissue could give a more accurate result in terms of 
DNA methylation with respect to the whole CRC tissue. From data elaboration we did 
not observe statistically significant difference between the epithelial cells and the tissue 
without separation about the promoter methylation of APC, CDKN2A, MGMT and 
hMLH1 genes (see Table 11), although some patients showed individually a statistically 
significant difference between the two experimental conditions regarding the degree of 
methylation of these genes (data not shown). It could be useful to analyse a larger tumor 
samples to verify the real importance of this method. 
Concerning MS-HRM analysis we screened a total of 62 CRC samples obtained from 
the surgical resection of patients at different stages as well as 48 adjacent healthy colon 
tissue. APC resulted the most frequently methylated gene in our cohort, showing 
promoter methylation in almost  50% of CRC tissues. This is the only gene that showed 
also a low percentage of methylation (0-12.5%) in 39% of adjacent normal tissue (see 
Table 6). The CDKN2A gene showed promoter methylation in 26% of CRC tissues, 
while the corresponding adjacent tissue did not show altered levels of methylation (see 
Table 7). Concerning the MGMT gene we observed a 35% of tumor tissues methylated, 
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and also a weak methylation (0-12.5%) in 13% of adjacent normal tissues analyzed (see 
Table 10). hMLH1 and RASSF1A are the least methylated genes in both tissues, found 
to be methylated in less than 15% of the analyzed samples (Tables 8, 9). The low levels 
of methylation observed in our study in normal appearing colorectal mucosa may be 
due to the circumscription of this phenomenon to limited area, rather than a spread 
diffuse alteration throughout the colon. We then performed a multivariate analysis of 
variance to test the effect of age, gender, cancer location, tumor size, and tumor stage to 
the levels of promoter methylation of each of the studied genes. In our cohort we did 
not find any statistically significant association between stage (TNM), gender, sex, 
tumor size, and location with regard to the methylation profile of each of the analyzed 
genes. However, we found an interesting positive association between age and both 
hMLH1 (P value= 0.007) and MGMT (P value= 0.03) methylation (Figure 25, 26).  
Several investigators reported association between methylation of CRC-related genes in 
relation to one-carbon metabolites and polymorphisms of the genes involved in one-
carbon metabolism (reviewed in Coppedè, 2011). Our investigation of the correlation 
between MTHFR 677C>T, DNMT3B -149C>T and gene promoter methylation revealed 
several significant interactions.  
 
The maintenance of cell–cell interactions is crucial to avoid unregulated cell growth. The 
Apc protein plays an important role in cell adhesion via β-catenin. Since the APC gene 
is a tumor suppressor gene, both alleles should be inactivated for cancer 
development. These two independent events could be allelic imbalance, promoter 
hypermethylation or mutations. The analysis of APC methylation in DNA from tumor 
tissues and corresponding normal tissues of 5 FAP patients revealed hypermethylation 
of the gene in tumor tissues of one proband and her son. No methylation was present in 
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normal tissues. Loss of heterozygosity was observed in another patient from the same 
FAP family. Thus aberrant methylation of the APC promoter region provides an 
important mechanism for impairing APC function and may occur early during colon 
neoplasia progression (Zhang et al., 2008). According to present results, another study 
revealed that the methylation status of APC had no significant association with clinical 
parameters (Naghibalhossaini et al., 2011). According to Lao and Grady (2011) MGMT 
and hMLH1 are frequently methylated in the polyp/adenoma  metastasis transition. 
Although we failed to find a significant effect of tumor stage to their promoter 
methylation profiles, the methylation levels of both of them showed a significant 
correlation with increasing age. According to our results, a previous study reported that 
the prevalence of hMLH1 and MGMT methylation increases significantly with age 
(Menigatti et al., 2009). Moreover, an association of MGMT promoter methylation with 
age and tumour grade was also observed in breast cancer tissues (Tserga et al., 2012). 
Interestingly both genes are involved in DNA repair processes and their methylation 
might reflect an age-related decline of DNA repair capabilities. During the last years an 
increasing number of genes has been reported to be affected by methylation changes 
during aging. Up to 70% of CGIs found to be hypermethylated in primary colon tumors, 
was due to an age-related increase in hypermethylation of the normal colon; in the same 
way of the hypermethylation of specific CGIs, the genomewide and locus-specific loss 
of methylation occurs as a direct function of age (Wojdacz and Hansen,  2006).  
p16
Ink4A
 and RASSF1A are also frequently methylated in CRC tissues. According to Lao 
and Grady (2011) p16
Ink4A
 is frequently methylated in the aberrant/crypt focus 
polyp/adenoma passage, and RASSF1A seems more methylated in the last stages or in 
metastases (see Migheli and Migliore, 2012). It is however noteworthy to say that none 
of these genes is stage specific and they are often methylated in different CRC stages, as 
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we observed in the present study. Here, no correlation among promoter methylation and 
CRC stage, location and size was observed, nor it was associated with patient age at 
sampling. Recent studies also suggest that CRC is not an unique disease in terms of 
DNA methylation, and at least 3-4 different CRC subtypes can be recognized according 
to high-low frequency of DNA methylation, chromosome instability and point 
mutations in selected genes (Hinoue et al., 2012). This might also partially explain 
some of the conflicting results observed in the literature. 
DNA methylation is largely depending from the availability of one-carbon nutrients and 
is mediated by DNA methyltransferases (DNMTs), of which three active forms have 
been identiﬁed: DNMT1, DNMT3A, and DNMT3B. The DNMT3B gene, located on 
chromosome 20q11.2, contains a C-to-T  transition polymorphism in the promoter 
region of  the gene, -149 base pairs from the transcription start site. A case-control study 
reported that this polymorphism is associated with increased risk of CRC (Zhu et al., 
2012). Difference in the promoter activity of the variants could affect DNMT3B activity 
on DNA methylation, thereby modulating the susceptibility to cancer. In an in vitro 
assay this polymorphism was found  significantly increase promoter activity of the 
DNMT3B gene. It was postulated that the T variant may up-regulate DNMT3B 
expression, resulting in a predisposition towards aberrant de novo methylation of CpG 
sites in tumor suppressor and DNA repair genes (Jair et al., 2006).  
We observed some positive correlations between the DNMT3B -149C>T polymorphism 
and the levels of methylation of APC, CDKN2A, hMLH1 and MGMT genes (see Figures 
37, 38, 39, 40). Albeit preliminary and obtained in a small group of patients our data are 
corroborated by previous findings by others suggesting that DNMT3B polymorphisms 
are associated with p14ARF methylation in CRC tissues. The authors investigated 
however a different polymorphism in the same gene (Kang et al., 2008). 
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MTHFR is an enzyme that converts 5,10 methylenetetrahydrofolate to 5-
methyltetrahydrofolate, the prevailing form of circulating folate and the methyl 
donor for the conversion of homo-cysteine to methionine. The 677T variant is 
associated with reduced enzyme activity (van der Put et al., 1998), and the 
MTHFR 677TT genotype was associated with a lower risk (0.68) of colorectal 
cancer compared with the homozygous CC genotype (Lee et al., 2012). Several 
previous studies suggest association between the MTHFR 677C>T polymorphism and 
gene methylation in CRC tissues, including hMLH1, CDKN2A genes (Mokarram et 
al., 2008; Zhu et al., 2011). There is also plenty of data on association between one-
carbon nutrients (folate, vitamin B12, vitamin B6), their interaction with alcohol 
consumption, and DNA methylation in CRC (reviewed in Coppedè, 2011). Here, we 
observed significant associations between the MTHFR 677C>T polymorphisms and 
methylation of hMLH1 and APC genes (Figure 33, 35). Interestingly, a study showed 
that in HCT116 cells, the MTHFR 677T mutation was associated with a significant 
increase in DNMT activity; this may be due to a compensatory response to the 
decreased SAM concentrations to maintain a critical level of DNA methylation (Batra 
et al., 2007). Parallel to the observed increased DNMT activity, the MTHFR 677T 
mutation in HCT116 cells was associated with a significant increase in DNA 
methylation at sufficient or very high folate concentrations. At a low folate 
concentration, the MTHFR 677T mutation was associated with a significant reduction 
in DNA methylation, according to the observation that the MTHFR C677T 
polymorphism is associated with genomic DNA hypomethylation in human 
lymphocytes only with low folate intake (Sohn et al., 2009; Castro et al., 2004). 
These results indicate possible MTHFR-DNMT interactions and gene-nutrient 
interactions to be investigated as soon as we could collect a larger cohort of subjects. 
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Moreover, several interactions among age at sampling, gene polymorphisms and 
DNA methylation have been observed, deserving confirmation in a larger cohort of 
subjects. 
Although the molecular mechanisms responsible for aberrant DNA methylation during 
carcinogenesis are still not well characterized, the implications of DNA 
hypomethylation and hypermethylation in the etiology of CRC tumorigenesis have 
become quite clear. Since epigenetic modifications are reversible, methylation studies 
are extremely promising to better characterize CRC and to identify new tools for 
diagnosis and prognosis. An interesting non-invasive method has been proposed for 
diagnostic evaluations of preclinical samples to detect cancer-derived methylation of 
vimentin gene in plasma and fecal DNA from colon cancer patients (Chen et al., 2005, 
Li et al., 2009). To date, a few pharmacological compounds directed toward epigenetic 
enzymes have shown promise in treating leukemias and lymphoma. These include DNA 
demethylating agents or (DNMT) inhibitors such as 5-azacytidine and 5-aza-20-
deoxycytidine and HDACi such as suberoylanilide hydroxamic acid (SAHA). DNMT 
and HDACi are still being tested in metastatic CRC patients to improve the quality of 
life and survival of patients in the near future (Crea et al., 2011). Interestingly a study 
showed an increase in the expression of DNMT1 in a colon tumor group of animals as 
compared to healty controls; moreover, the rats treated with 5-azacytidine alone or with 
combination of 5-azacytidine and cisplatin showed significant reduction in the 
expression of DNMT1, resulting in a protection against tumor growth (Tikoo et al., 
2009). 
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